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Abstract 
 
Fuad Bahram, 2004. Post-translational regulation of Myc oncoprotein function 
Doctor’s dissertation 
ISSN 1401-6249, ISBN 91-576-6495-1 
 
 
The c-Myc proto-oncogene encodes a transcription factor that controls genes involved in 
cell cycle regulation, cell growth, apoptosis and other cellular processes together with its 
partner Max. c-Myc has been shown to be altered in a wide variety of human tumors.  
This thesis focuses on post-translational regulation of Myc function. The aims was firstly to 
elucidate mechanisms of regulation of Myc degradation and components involved, and 
secondly to understand the mechanism(s) behind IFN-γ-induced inactivation of Myc. 
The c-Myc oncoprotein is short–lived phosphoprotein. We have found that Myc is tightly 
regulated via ubiquitin/proteasome-mediated turnover and that mutation of the Thr-58 
phosphorylation site, which is frequently mutated in both in Burkitt’s lymphoma leads to 
stabilization of c-Myc. We have further established that the E3-ubiquitin ligase SCF
Skp2 
associates with c-Myc in late G1 and S-phase of the cell cycle, inducing not only ubiquitin-
mediated degradation of c-Myc but surprisingly transcriptional activation of c-Myc target 
genes. Skp2 as well as proteasomal subunits were shown to be recruited to a Myc target 
promoter in vivo in a Myc-dependent manner. The second part of the thesis shows that the 
cytokine IFN-γ restore differentiation and cell cycle arrest in v-Myc expressing monocytic 
cells  through inhibition of Myc-induced transcription, Myc DNA-binding and 
destabilization of Myc:Max heterodimers, correlating with dephosphorylation of Myc. We 
further found that IFN-γ reduces phosphorylation of Ser-62 and increases 
ubiquitin/proteasome-mediated degradation of Myc in a Ser-62 dependent 
manner.CycE/CDK2 was identified as a Ser-62 kinase in vivo and in vitro. IFN-γ-induced 
degradation and Ser-62 dephosphorylation correlated with inactivation of CDK2 through 
p27
Kip1, which was shown to be required for this process. In conclusion, the thesis suggests 
that ubiquitin/proteasome-mediated turnover is an essential level of regulation of Myc 
function that may have important future implications for treatment of tumors with 
deregulated Myc expression. 
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Abbreviations 
 
 
 
GTF   General  Transcription  Factor 
TBP   TATA-box  binding  protein 
IFN-γ    Interferon-γ 
JAK1     Janus kinase 1 
STAT1    Signal Transducer and Activator of Transcription 1 
MBI, II    Myc box 1, II 
HAT    Histone  acetyltransferase 
HDAC   Histone  deacetylase 
Odc      Ornithine  decarboxylase 
pRb      Retinoblastoma  protein 
TAD      Transactivation  domain 
CTD      C-terminal domain  
bHLHzip  basic region helix-loop-helix leucine zipper 
SID       Sin3-interacting domain  
Cdk       Cyclin dependent kinase 
CIP1      Cdk inhibitor protein 1 
CK       Casein  kinase 
CKI       Cyclin dependent kinase inhibitor 
INK4       Inhibitor of Cdk4/6 
CAK    CDK  activating  kinase 
JNK       Jun N-terminal kinase 
MAPK     mitogen activated protein kinase   
MEF      murine embryo fibroblast 
aa       amino  acid 
PDGF     platelet-derived growth factor 
Skp2      S-phase kinase-associated protein 2 
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Background 
 
Development of cancer 
The development of cancer is no longer a mystery; during the last 2-3 decades 
numerous researchers have made fabulous progress in their work to clarify the 
basis of the process. 
In reality the term cancer refers to hundreds of forms of the disease. Almost all 
organs or tissues can be subjected to tumor development, some of which can 
manifest several cancer types.  One common question, why a cell becomes a 
cancer cell? 
The nearly 30 trillion cells living in the human body are regulating each another’s 
growth and survival in a well organized but complex manner.  Indeed, normal 
cells reproduce only when they are instructed to do so by signals from other cells 
in their vicinity. In contrast, cancer cells follow their own agenda for reproduction, 
and also eventually become more aggressive, emigrating and invading nearby 
tissues or forming tumor masses at sites distant form the sites of their origin.  
Many years before a tumor becomes visible, usually multiple genetic alterations 
have occurred. Mutations in a gene can result in altered amounts or altered activity 
of the gene product. Two different classes of genes are important for the 
development of cancer, proto-oncogenes, which are involved in stimulation of cell 
growth and tumor suppressor genes, which inhibit it. Mutations in a proto-
oncogene can result in its transformation into a carcinogenic oncogene caused 
either by deregulated expression or by the creation of an overly active form of the 
gene product, both resulting in growth stimulation. Tumor suppressor genes in 
contrast normally protect the organism from cancer by inhibiting cell growth, and 
mutations in such genes may result in inactive genes or gene products which are 
unable to brake cell growth, again leading in cancer (Hanahan and Weinberg, 
2000, Macleod, 2000).  
Genetic alterations in multiple genes affecting multiple fundamental biological 
processes are needed to create a cancer cell. Below some of these processes are 
described as summarized in figure 1.  
Normal cells require growth signals before they can exit from a quiescent state 
into actively growing state. In adults, cells normally divide only when cells new 
are needed to replace damaged or worn out tissue. In contrast, tumor cells grow 
uncontrolled. Such external growth signals are transferred through soluble factors 
or cell-cell interactions. The signals are usually received by specific receptors at 
the cell surface, after which the signals are transmitted from the receptors into the 
cell interior, through signaling pathways involving G-protein-coupled receptors, 
GTPaes, tyrosine kinase and MAPK, etc. Numerous of oncogenes operate by 
mimicking such normal growth signaling pathways. Activation or overexpression 
of surface receptors or components of the downstream mitogenic signal pathways 
such as the epidermal growth factor receptor (EGF-R), (Balmer et al., 2001) and 
Ras, has been found in many cancers (Boettner and Van Aelst, 2002). 
 
Insensitivity to antigrowth signals is another common genetic alteration in order 
for cancer cells to multiply. Normally the cell’s decision whether to growth and 
not is determined by the balance between growth and anti-growth signals. Anti- growth signals can block cell growth by two different ways, either by inducing 
cells to exit the cell cycle into a reversible G0-phase or by causing cells to move 
toward a more permanent postmitotic phase through differentiation or senescence. 
There are specific antigrowth molecules which involve signaling pathways similar 
to those induced by growth signals. Examples of such antigrowth molecules are 
the interferons including (IFN-α, β and γ) and the TGF-β family. IFNs interact 
with multisubunit transmembrane IFN-receptors, which associate with tyrosine-
specific Janus activating kinases (JAKs) at the inner side of the plasma membrane. 
Following activation of JAKs by IFN-signaling. Latent transcription factors 
located in the cytosol called Signal Transducer and Activator of Transcription 
(STATs) become phosphorylated and translocate to the nucleus as a dimers where 
they activate transcription of genes that negatively regulate cell growth (Sangfelt 
et al., 2000, Brivanlou and Darnell, 2002)(see below). TGF-β bind typ I and II 
serine/threonine kinase receptors at the cell surface that transmit signals through 
another type of latent transcription factors, Smads, which translocate into the 
nucleus and regulate the transcription of TGF-β responsive genes. Disabling of the 
TGF-β pathway affecting its components by mutations thus removes a barrier that 
normally prevents the cells to proceed through the cell cycle (Shi and Massague, 
2003). 
 
 
 
 
 
 
Growth signals
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Insensitivity to  
Resistance towards  Antigrowth signals
Apoptosis   
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Genetic   Block 
 Instability
Metastasis Circumvention of   Induction of 
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Figure 1: The cellular processes during genetics alteration in cancer cells  
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Cancer cells also need to block programmed cell death (apoptosis) to survive. 
Apoptosis is an essential regulatory mechanism that occurs in all normal cells 
characterized by programmed cell death. However, tumor cells develop an ability 
to resist apoptosis. The most common strategy is the loss of the pro-apoptotic 
tumor suppressor gene p53 through mutations that result in functionally inactive 
p53. Mutation can also occur in the MDM2 gene which encodes a negative 
regulator of p53. The Bcl-2 family of proteins is another component involved in 
apoptosis control. Those with anti-apoptotic actions include Bcl-2, Bcl-xl and Bcl-
w and among those with pro-apoptotic action are Bax, Bak, Bid and Bin. 
Overexpression of the Bcl-2 oncogene through mutations occurs in many tumors 
(such as B-cell lymphoma) and leads to inhibited apoptosis. Upregulation of Bax 
by p53 activation can elicit apoptosis. Caspases (a group of cysteine proteases) is a 
group of proteins that play major role in executing the apoptosis program. 
Caspases can be activated by signaling through death receptors such as the FAS 
protein (the so called extrinsic pathway) or directly by cytochrome C release from 
the mitochondria (the so called intrinsic pathway) (Igney and Krammer, 2002). 
 
Another hallmark of tumor cells is genetic instability that is manifested at the 
chromosomal level. Cancer cells accumulate genetic alterations, including 
translocations and amplifications leading to abnormal gene expression or 
abnormal gene products. In Burkitt’s lymphoma, rearrangements involving 
chromosome 8 and 14 (90% of cases) lead to abnormal expression of the c-Myc 
oncoprotein as consequence of being translocated into vicinity of any of 
immunoglobulin heavy chain enhancers. Normally, DNA can be replicated only 
once per cell cycle. However in cancer cells, some regions undergo multiple 
rounds of replication called amplification. A typical example of this type of 
process is amplification of the myc gene in neuroblastomas (Oster et al., 2002). 
 
Human cells have a cell autonomous program that limits their multiplication 
potential (to approximately 50 divisions). Cancer cells must disrupt also this 
program to expand and develop into immortal tumors. Telomeres, the ends of the 
chromosomes are composed of several thousand repeats of a six base pair 
sequences that appear to act as a counting tool for cell doubling. During every cell 
doubling, the chromosome loses 50-100 base pair of telomeric DNA due to the 
inability of DNA-polymerases to completely replicate the ends of the 
chromosomes. After reaching a critically short telomere length, the senescence 
machinery of the cell is activated and the cell will then undergo senescence. In 
almost all cancer cells telomere maintenance is achieved by activation of the 
telomerase enzyme which add telomeres to the ends of chromosomes after they 
divide, thereby which is avoiding senescence (Cech, 2004). 
 
Proliferating cells require both oxygen and nutrients to survive and grow. Cells do 
not normally have the ability to initiate and induce blood vessel formation, a 
process knows as angiogenesis; hence tumor cells have to develop this ability to 
survive. Activation of angiogenesis inducers, such as vascular endothelial growth 
factor (VEGF) has been found in many tumors (Ferrara, 2002). In addition to 
angiogenesis, cancer cells also develop the ability to move out and invade nearby 
tissues by metastasation. Numerous proteins have found to be involved in this   12
process such as E-cadherin and β-catenin which has been inactive in many types 
of tumors. 
 
The Eukaryotic Cell Cycle 
The Eukaryotic cell cycle is divided into four phases, G1 (gap 1), S (DNA 
Synthesis), G2 (gap 2) and M (mitosis), see Figure2. In G1 the cell prepares itself 
for DNA replication that occurs during S-phase. The G2-phase allows preparation 
for chromosome segregation and cell division during mitosis. In addition to these 
phases, the cells can also enter an inactivate phase (G0) during development, 
differentiation or growth factor depletion. To ensure that cells pass accurate
 copies 
of their genomes on to the next generation, evolution has
 overlaid the core cell-
cycle machinery with a series of surveillance
  pathways termed cell-cycle 
checkpoints. These checkpoints of the cell cycle ensure faithful DNA replication 
and separation of the chromosomes at cell division thereby sustaining genetic 
stability. Any alteration or failure of these checkpoints to arrest the cells can result 
in cancer development (Malumbres and Barbacid, 2001) During G1, cells typically 
respond to proliferative or antiproliferative signals, which determine whether the 
cell should continue cell cycle progression or arrest at G1/G0-phase. Cell cycle 
progression is regulated by two classes of cell cycle regulatory proteins, the 
cyclins (Cyc) and the cyclin dependent-kinases (CDKs). The cyclins can be 
divided into G1 cyclins (CycD and E), S-phase cyclins (CycA), and mitotic 
cyclins (CycA and B). CycB and A bind and activate CDK1 (cdc2) during G2 and 
M-phase. The CycD family consisting of D1, D2 and D3 bind and activate CDK4 
and CDK6, while the CycE family (CycE1 and E2) interact with and activate 
CDK2. Both CycD/CDK4 or 6 and CycE/CDK2 acts as positive regulators of G1 
to S-phase transition through phosphorylation of the retinoblastoma tumor 
suppressor protein (pRb). The active unphosphorylated form of pRb arrest the 
cells at the restriction point in the late G1-phase of the cell cycle, at least in part 
through interaction with the E2F-family (including E2F1-3) of DNA binding 
transcription factors, (Harbour and Dean, 2000). The ability of pRb to arrest cells 
in G1-phase of the cell cycle is seems to be dependent upon the transcriptional 
repression of E2F target genes by the Rb/E2F complexes through requirement of 
histone deacetylases (Magnaghi-Jaulin et al., 2000). Progressive phosphorylation 
of pRb through G1-phase leads to release of E2F from pRb. This switches E2F 
from a repressor to an activator and allows activation of the transcription of E2F 
target genes, (Lavia and Jansen-Durr, 1999), involved in DNA replication.  
On the other hand, a diverse set of negative cell cycle regulatory proteins 
including cyclin-dependent kinase inhibitors (CKIs), many of which act as tumor 
suppressors, have been identified. The CKIs consist of two families, the Cip/Kip 
family including p21
Cip1, p27
Kip1 and p57
Kip2  and the INK family including 
p16
INK4A, p15
 INK4B, p18
 INK4C and p19
 INK4D. The Cip/Kip families negatively 
regulate the cell cycle through binding to an inactivation of CDK2 complexes. 
Formations of heterotrimeric CDK4 or 6-CycD-Cip/Kip complexes contribute to 
G1 progression by sequestration of these inhibitors, preventing them from binding 
and inactivating CycE/CDK2 complexes (Sherr and Roberts, 1999). Formation 
and activation of CycD/CDK4 or 6 complexes is however, potentiated by 
Cip1/Kip1, for review see (Swanton, 2004). The activity of CDK4/6 is negatively 
regulated by the INK4 family by preventing CycD binding, see Fig2. Many   13 
antiproliferative signals such as  IFNs and TGFβ upregulate members of the two 
CKI families resulting in inactivation of CDK4/6 by Ink4 families leading to 
disruption of CycD/CDK/Cip/Kip complexes and release Cip/Kip from the 
complex. Cip/Kip can in turn interact with and inactivate CycE/CDK2 complexes 
thereby causing cell cycle arrest in G1/G0. CycE/CDK2 once activated 
phosphorylates p27
Kip1 on Thr-187, after which it is recognized by SCF
Skp2, which 
induces its ubiquitin-mediated degradation by the proteasome. In addition to 
cyclins and CKIs, CDKs can also be regulated by modifications. The amount of 
the CDKs remains constant throughout the cell cycle but the activity can be 
regulated via phosphorylation or dephosphorylation. Phosphorylations on 
threonine 14 or tyrosine 15 by the wee1/mik1 protein kinases inactivate CDKs. 
The phosphatases Cdc25A-C activate CDKs by dephosphorylation of these 
residues. Furthermore, CDKs can also be activated by phosphorylation of a 
conserved threonine residue at position 160 by CDK-activating kinase (CAK). The 
steady state levels of both cyclins and Cip/Kip proteins are not only regulated by 
through gene expression but also by turnover via the ubiquitin-proteasome 
pathway, for review see (Hershko and Ciechanover, 1998). 
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Figure 2: Cell cycle regulators 
Schematic presentation of the mammalian cell cycle. A, mammalian cell cycle is divided 
into four phases, G1, S, G2, and M. Progression from one phase to the next is regulated by 
Cdks associated with their cyclin subunits. Inhibition of the cyclin-Cdk complexes is 
mediated by two families of cdk inhibitors, Ink4 proteins (p16Ink4a, p15Ink4b, p18Ink4c, 
and p19Ink4d) and Cip/Kip proteins (p21Cip1, p27Kip1, and p57Kip2). Whereas Ink4 
proteins specifically bind to and inhibit cdk4/6, Cip/Kip family members can inhibit 
cyclin/Cdk complexes including cyclin E-Cdk2, cyclin A-cdk2, and cyclinB-cdk1 Cip/Kip 
proteins can also positively regulate cyclin D-Cdk4/6 by promoting their assembly. CycD-
cdk4/6 and cyclin E-Cdk2 complexes phosphorylate (P) pRb, result in release from the 
transcription factor E2F. Free E2Fs (1, 2, or 3) bind to their DP partners and activate the 
transcription of genes necessary for S phase entry. 
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Transcriptional regulation 
The regulation of gene expression of protein-encoding genes is a complicated 
multi step process that starts with initiation of the transcription by RNA 
polymerase II at specific DNA sequences called promoters. RNA pol II binding to 
DNA can not specifically start transcription, additional factors, so called general 
transcription factors (GTFs), interacting directly or indirectly with RNA pol II are 
required for this process, and include enzymes with the ability to open up the 
DNA doublehelix and to initiate and elongate transcription. The GTFs include 
TFIIA, TFIID, TFIIB, TFIIE, TFIIF and TFIIH (Burley and Roeder, 1996). TFIID 
is a multi complex of proteins including TBP (TATA-box Binding Protein) 
(Comai et al., 1992), which directs binding to TATA-boxes A TATA-box is a 
T/A-rich promoter sequence located 25-30 base pairs upstream the 5`end of a 
gene, which determines the transcriptional start site. In addition to TBP, TFIID 
contains other components known as TAFs (TBP associated factors) (Hernandez, 
1993). The binding of TBP to the DNA, bents the DNA and creates a platform for 
the interaction with other transcription factors (Hoffman et al., 1990). TFIID 
binding to DNA is followed by TFIIA binding to the amino terminus of TBP, 
thereby protecting TFIID from inhibition by transcription repressors. In contrast, 
TFIIF interacts with carboxy-terminus of TBP, acting as a bridge between TBP 
and RNA pol II, in association with another factor TFIIB. This binding is essential 
step in pre-initiation complex formation since TFIIB in addition to TFIID can also 
bind to the RNA-pol II it self. TFIIB further recruits the TFIIH complex. 
Following TFIIB-mediated binding of RNA polymerase II to the promoter, TFIIE, 
IIH and IIJ associate rapidly to the pre-initiation complex. The TFIIH complex, 
which contains helicase and kinase activities, catalyzes the ATP-dependent 
melting of the promoter at the transcriptional start site. The DNA doublehelix 
opens and thereby allowing it to be transcribed into RNA, (Wu et al., 1998). The 
kinase activity of TFIIH consists of the cyclin H and CDK7 complexes which 
phosphorylates the carboxy-terminal domain (CTD) of RNA-pol-II. This 
phosphorylation stimulates promoter escape and elongation, probably by 
preventing the binding of negative elongation factors such as DSIF and NELF 
(Conaway et al., 2000). TFIIH activity is dependent on TFIIE binding to the pre-
initiation complex. Both TFIIE and TFIIH are required for promoter escape and 
transcription elongation (Reese, 2003). The positive transcription elongation factor 
b (P-TEFb) complexes contain a common catalytic subunit (CDK9) and the 
unique regulatory cyclins Cyc T1, CycT2a and Cyc2b. P-TEFb has been suggested 
to phosphorylate the CTD of RNA pol II and allowing the elongation of 
transcription to proceed (Peng et al., 1998, Wei et al., 1998).  
 
DNA binding transcription regulators 
In order to activate or repress transcript for instance in response to cellular 
signaling, DNA binding transcription factors that specifically recognize promoter 
or enhancer elements within the DNA control regions of genes are required to 
recruit RNA polymerase II to the promoter. The DNA-binding transcription 
factors can act as activators or repressors of transcription (reviewed in Lemon and 
Tjian), and possess at least two essential domains: a DNA-binding domain (DBD)   16
and a transactivation domain (TAD). The negative regulating transcription factors 
possess a domain that is capable of repressing recruitment of Pol II or through 
binding to corepressors. The DNA binding transcription factors have been 
classified according to their structural motifs. One of these is the homoeodomain, 
which is a highly conserved domain of 60 amino acids found in a large family of 
transcription factors. The homeodomain itself forms a structure highly similar to 
the bacterial helix-turn-helix proteins. The DNA binding can further be mediated 
by the helix-loop-helix (HLH), domain which is involved in protein dimerization. 
The HLH motif is composed of two regions of a-helix separated by a region of 
variable length which forms a loop between the 2 alpha-helices. This class of 
transcription factor most often contains a region of basic amino acids located on 
the N-terminal side of the HLH domain (termed bHLH proteins) that is necessary 
in order for the protein to bind DNA at specific sequences. The HLH domain is 
necessary for homo- and heterodimerization. Examples of bHLH proteins include 
c-Myc. Another DNA-binding motif is the zinc finger domain consisting of 
specific sequences of cysteine and histidine residues that allow the protein to bind 
zinc atoms. The finger domains can penetrate into the major groove of the DNA 
helix. The spacing of the zinc finger domain in this class of transcription factor 
coincides with a half-turn of the double helix. The classic example is the RNA pol 
III transcription factor, TFIIIA. Proteins of the steroid/thyroid hormone family of 
transcription factors also contain zinc fingers. POU domain is a domain that is a 
hybrid between a domain related to the homeobox and conserved domain, the 
POU-specific domain (for review see Ryan and Rosenfeld). The leucine zipper is 
another domain essential for protein dimerization. These leucine residues end up 
with their R-groups protruding from the a-helical domain in which the leucine 
residues reside. The protruding R-groups are thought to interact with leucine R 
groups of another leucine zipper domain, thus stabilizing homo- or 
heterodimerization. The leucine zipper domain is present in many DNA-binding 
proteins, such as c-Myc, and C/EBP.  
 
Coactivators and corepressors 
The understanding of transcription factor function requires knowledge of the 
nature and effect of interaction between 2000-3000 different transcriptions 
regulators that animal cells make use of. The direct interactions between activators 
and the basal machinery is necessary for activation of transcription stimulation, 
and an additional class of factors, referred to as cofactors, adaptors and mediators 
are also considered to be fundamental to this process. Studying the role of these 
co-activators and co-repressors is essential to understanding transcriptional 
regulation in eukaryotes. Transcriptional cofactors can be classified into five 
classes according to the structure of their DNA binding domains. The TAFs of the 
initiation factor TFIID fits into the first class. The cofactors that is associated with 
activator or repressor molecules at the promoter fits into second class. Such as 
cellular factors OCA-B, Groucho, Notch, CtBP, HCF and viral coregulators E1A 
and VP16. summarized in (Lemon and Tjian, 2000).  
The cofactor that is multisubunit coactivators are classified as the third class. One 
example is the yeast mediator (Thompson et al 1993., Kim et al., 1994). The yeast 
mediator was originally purified as an activity that was believed to facilitate the   17 
stimulation of activator-dependent transcriptional activity in reconstituted 
transcription reactions. Additionally the TFIIH dependent phosphorylation of CTD 
was also found to be stimulated by the yeast mediator interacts with the CTD of 
PolII.  The mediator consists of components such as a subset of SRB polypeptides 
and several previously uncharacterized proteins (Med1-Med7) (Thompson et al 
1993., Kim et al., 1994, Koleske and Young, 1994, Myers et al., 1998). 
Furthermore, the yeast mediator was found to copurify with a proposed 
subcomplex containing the Srb8 Srb9, Srb10/Cdk8 and Srb11/cyclin C 
polypeptides. These polypeptides have been suggested to be involved in negative 
regulation of gene activity.    
 
Metazoan mediator-like complexes have been subsequently identified: (i) CRSP 
and PC2 (Ryu and Tjian, 1999, Malik et al., 2000), (ii) ARC/DRIP/TRAP (Gu et 
al., 1999, Ito et al., 1999, Naar et al1999) and (iii) NAT/SMCC/Srb-mediator (Sun 
et al., 1998, Gu et al., 1999) Many components of mediator-like complexes have 
been found to interact with transcriptions factors as corepressors or coactivators, 
which implicates inhibition or enhance transcription. Class IV includes those 
cofactors that are covalently modified nucleosomes, see below. The cofactors that 
hydrolyze ATP in catalytic reactions to reorganize are classified as class V.  
 
Chromatin and transcriptional regulation 
Eukaryotic DNA in contrast to prokaryotic is packaged by association with 
histones to form a structure known as chromatin, (Latchman, 1996). The 
fundamental unit of this structure is the nucleosome in which the DNA is wrapped 
twice around an octamer of histone molecules (two of each histone H2A, H2B, H3 
and H4). This structure is compacted further in genes which are transcriptionally 
not active. Transcriptional activation of these such genes requires modulation of 
chromatin structure by altering the position and conformation of nucleosomes 
thereby facilitating the transcription factors to bind to the promoter or enhancer 
region of the genes. During the last decade, at least two mechanisms behind the 
alteration of the chromatin structure have been recognized involving at least two 
different classes of enzymes that can be targeted to the promoters by interaction 
with transcription coactivators. The first class includes ATP-dependent chromatin 
remodeling complexes such as SWI/SNF, ISWI, RSC and Mi-2/NuRD complexes. 
These complexes change the chromatin structure by altering the nucleosome 
location without involving any covalent modifications. One example is the 
proteolytical member of chromatin-remodeling complexes, SWI/SNF that alters 
chromatin structure by changing the location or conformation of the nucleosome 
without covalent modification. Some types of activators have been shown to 
physically or functionally interact with SWI/SNF activities. Such as the C/EBPβ 
activator and the  c-Myc proto-oncoprotein that binds directly to subunits of 
mammalian SWI/SNF complexes, reviewed in (Naar et al., 2001).   
 
 
Histone modification 
The second class of enzymes alters the chromatin structure through modification. 
The histones can be subjected to a number of post-translational modifications such 
as acetylation, methylation, phosphorylation and ubiquitylation (Strahl and Allis,   18
2000, Wu and Grunstein, 2000). Acetylated forms of histones have been found 
preferentially in active genes where the chromatin is less tightly packed. This 
suggests that hyperacetylation of histones could play causal role in opening the 
chromatin structure, A number of enzymes with histone acetyltransferase (HAT).  
HAT activity modifying lysine residues at the histone tails have been found, 
among these GCN5, Esa1, MOF in yeast, and GCN5/PCAF, Tip60 and  CBP/p300 
in mammalian (Bannister and Kouzarides, 1996, Ogryzko et al., 1996, Cheung et 
al., 2000b). The connection between transcription activation and acetylation has 
been confirmed by demonstration that yeast GCN5 protein which is a positive 
regulator of transcription of many genes, has HAT activity, (Georgakopoulos and 
Thireos, 1992, Brownell et al., 1996). Mutation of the catalytic domain of GCN5, 
results in inactivation of the transcription, and abolish the acetylation of histones, 
(Kuo et al., 1998, Zhang et al., 1998). In addition to GCN5, many other 
coactivators such as TAFII250, SRC-1 ACTR have intrinsic HAT activity that is 
important for their transcriptional role (Schiltz and Nakatani, 2000, Sterner and 
Berger, 2000, Wu and Grunstein, 2000). HATs often function as part of 
multisubunit complexes such as 2 MDa SAGA and 1 MDa ADA complexes, 
(Grant et al., 1997). In addition, the SAGA complex contains several serine 
palmitoyltransferase (SPT) proteins which act as a bridge with TBP, the ATM/PI-
3 kinase related protein Tra1, TBP associated factor TAFII250 and Ada proteins 
(Ogryzko et al., 1998). 
There are also histone deacetylases (HDACs) that remove acetyl groups from 
lysines in N-terminal tails of histones. While hyperacetylation of histones have 
been correlated to a transcriptionally active state, hypoacetylation or deacetylation 
correlates with a transcriptionally repressed state. The connection between 
deacetylation and repression of the transcription was clarified by the isolation of 
human HDAC1 or in yeast Rpd3, (Struhl, 1998). Other members of deacetylase 
complexes were also identified such as the Rb associated proteins RbAp46 and 
p48 which required deacetylases and chromatin remodeling complexes to repress 
the transcription. Several transcription factors and nuclear receptors have also 
found to interact with complexes which contain HDAC activity such as 
NCoR/SMART and Sin3. The Myc antagonist, Mad proteins has found to interact 
with Sin3/ NCoR complexes to repress the expression of myc target genes and 
controlling the cell proliferation and differentiation. The mammalian transcription 
factor YY1 can also act as a repressor through its directly binding with histone 
deacetylase and NCoR/ Sin3 complexes, (Alland et al., 1997). 
Additionally, histones can also be modified by phosphorylation. Phosphorylation 
of Ser-14 is correlated with cells undergoing apoptosis (Cheung et al., 2000a, 
Cheung et al., 2003). Methylation of histones is another type of modification and 
found linked to transcription activation. Studies have shown that H3 and H4 are 
frequently methylated at lysine residues by methyltransferase (Chen et al., 1999). 
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Interferon-γ and STAT/JAK pathway 
Interferons (IFN) constitute a family of cytokines that includes three major classes 
called IFN-α, −β and-γ. IFN-α and  β belong to type I, while IFN-γ is more 
distantly related and belongs to type II.  Type II interferon has been widely studied 
and has been shown to carry out many biological functions, including antiviral and 
antiproliferative activities, expression of HLA I and II in transplantation antigens, 
activation of macrophages and regulation of apoptosis and cell differentiation 
(Boehm et al., 1997, Hu et al., 2002b). IFN-γ has in fact been considered as 
antitumor curative and has been used in treatment of certain human cancer, 
(Gleave et al., 1998). IFN-γ action is regulated in two different ways; control of 
IFN-γ production and modulation of IFN-γ signaling. The production if IFN-γ is 
regulated by T-cells receptor engagement in T-helper cells and by interleukin 12 
(IL-12,) and 18 (IL-18) in natural killer cells. Upon binding of IFN-γ to its 
receptor, the receptor associated tyrosine kinases Janus kinase 1 and 2 (JAK1, 
JAK2) become activated through auto phosphorylation of a specific tyrosine 
residue (Y440). This leads to activation of STAT1, by phosphorylation of specific 
tyrosine residue (Tyr-701) located in the Src-Homolgy 2 domain (SH2). This is 
common structural motif of STAT proteins and other signaling molecules that has 
shown to mediate protein-protein interaction. N-terminal of the SH2 domain is the 
linker domain (LD) which is also highly conserved among other STAT families 
and shown to be important for transcriptional response to IFN-γ but not IFN-α. 
Transcriptional activation is mediated by C-terminal domain and may further 
regulated by phosphorylation of conserved serine residue present in STAT1, 
STAT3, STAT4, STAT5α and STAT5β (Stark et al., 1998, Decker and Kovarik, 
2000). A coiled-coil domain in the N-terminus is required for protein-protein 
interaction, while the DNA binding domain is essential for binding to specific sites 
in the promoters of target genes STAT1 forms homodimer leading in translocation 
to the nucleus and binding to gamma activated sequences (GAS) IFN-γ target 
genes (Muller et al., 1993, Watling et al., 1993), see figure 3. Other studies have 
shown that STAT proteins may be activated through additional pathways 
including growth factor receptors and non-receptor with tyrosine kinases activity 
such as Src and Abl (Bowman et al., 2000). Other groups of proteins can 
negatively regulate cytokine signaling (Greenhalgh and Hilton, 2001). Among 
these are phosphatases such as SHP-1, which have shown to suppress cytokines 
receptor-mediated signals. The suppressor of cytokine signaling (SOCS) family 
can also inhibit cytokine signaling either through directly binding to JAK or 
through competitive binding to the activated receptors. In addition, the protein 
inhibitor of activated STATs (PIAS) family of proteins, suppress STAT signaling 
by directly interacting to STATs. In addition to the STAT-dependent pathway, 
IFN-γR can also signal through a STAT-independent pathway through activation 
of Ras/Raf pathway, also mediates biological responses, for review see (Stark et 
al., 1998). 
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Figure 3: IFN-γ signaling: 1) Component of IFN-γ Receptor α and β chains in absence of 
IFN-γ. 2) Aggregation of receptors component, Jaks are activated through auto-
phosphorylation activated Jak phosphorylate IFN-γ-Rα. 3) STAT1 binds to phosphorylated 
receptor and are then phosphorylated by Jaks. 4) Phosphorylated STAT1 form homodimer 
and translocate to nucleus, binds the DNA and activate transcription of target genes. 
 
 
 
The ubiquitin-proteasome system 
Eukaryotic cells use a variety of mechanisms to regulate gene expression at 
different level. Regulation at the posttranslational level can occur through various 
modifications such as phosphorylation, glycosylation, acetylation, sumolyation 
and ubiquitylation, etc thereby regulating protein activity or turnover. The 
ubiquitin-proteasome system provides a mechanism for regulating protein 
degradation. This involves two different and successive steps, attachment chain of 
76 a a protein molecule ubiquitin to the substrate and secondly degradation of the 
ubiquitylated substrate by the 26S-proteasome. The ubiquitin conjugation process 
proceeds through three enzymatic steps. The C-terminal Gly residue of ubiquitin is 
first activated in an ATP-requiring step by a specific activating enzyme, E1. In this 
step consists of formation of an intermediate ubiquitin adenylate, followed by the 
binding of ubiquitin to Cys residues of E1 in a thiolester linkage, with AMP 
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release. In the second step the activated ubiquitin molecular is next transferred to 
an active site of Cys residue of an ubiquitin carrier/conjugating enzyme E2 which 
transfers ubiquitin molecules from E1 either to one of the E3 enzymes which are 
called ubiquitin-ligases, or directly to the substrate with or without help of an E3 
ligase. The E3-ligases catalyze the conjugation process, resulting in covalent 
attachment of ubiquitin to a specific substrate (Hershko and Ciechanover, 1998, 
Weissman, 2001). Prior to the ubiquitylation process, the E3-ligase recognizes the 
substrate directly through specific recognition surfaces or indirectly through a 
secondary protein such as a molecular chaperone. In many cases, recognition by 
the E3 ligase requires posttranslational modification of the substrate. Ubiquitin-
E3-ligases are generally divided into three classes based on the specific structure 
motif they have. HECT-based E3-ligases such as E6-AP, RING-finger-based E3-
ligases including MDM2 and Cb1 and finally multi-protein subunit E3 ligase 
families. These are Cullin-based E3-ligases, including the anaphase promoting 
complex, the (von Hippel Landau tumor suppressor BC complex) VBC and the 
(Skp1-Cullin-F-box proteins) SCF complex.  SCF represents a large family of 
modular complexes consisting of the Cul1, Rbx1, Skp1, and F-box protein 
subunits. The Cul1 and Rbx1 subunits form a catalytic core that recruits the 
upstream E2 enzyme, the variable F-box subunit binds the substrate, and Skp1 
links the F-box subunit to Cul1. There are six cullin proteins and more than 50 F 
box proteins in the human genome (Ou et al., 2002) and this presumably allows 
the SCF to specify the ubiquitylation of numerous, diverse substrates (Deshaies, 
1999, Jackson and Eldridge, 2002, Zheng et al., 2002). One of the most studied F-
Box protein is Skp2 which has been shown to be interact with and promote 
degradation of p27, CycE, E2F, Myc, p130, and Cdk9 (Yu et al., 1998, Carrano et 
al., 1999, Tsvetkov et al., 1999, Carrano and Pagano, 2001, Yeh et al., 2001, 
Mendez et al., 2002, Kim et al., 2003, von der Lehr et al., 2003, Wei et al., 2004).  
Originally Skp2 was identified as S-phase kinase-associated protein 2 and plays an 
important role in cell cycle progression. Skp2 expression can be detected first near 
the G1/S transition and declines in G2. Overexpression of Skp2 in serum starved 
fibroblast has shown to induce p27
Kip1degradation and S-phase transition through 
induced expression and activation of CycA/CDK2, Cyc/Cdk2 (Mongay et al., 
2001). Moreover, Skp2 has been suggested to be an oncogene since it’s 
overexpressed in transformed cells (Gstaiger et al., 2001, Zhang and Wang, 2003).  
 
Connection between ubiquitylation and transcription 
Transcription activators are often short-lived proteins regulated by the ubiquitin-
proteasome pathway (Molinari et al., 1999). Recent studies have suggested a 
connection between the functional activities of many transcription factors and their 
ubiquitylation/degradation. The domains mediating degradation termed “degrons” 
and transactivation domains (TAD) have often found to be overlapping and 
functionally equivalent (Molinari et al., 1999, Salghetti et al., 2001). Recent 
reports has demonstrated that TAD-dependent ubiquitylation of transcription 
factor are also required for their function in transcription activation and not only 
for degradation (Salghetti et al., 2001). More direct evidence demonstrated that 
strains deficient in the F-box protein Met30 in yeast failed not only to ubiquitylate 
and degrade VP16, but also to function as a transcription activator, indicating that 
VP16 ubiquitylation by Met30-E3 ligase is needed not only for destruction but   22
also for activation (Salghetti et al., 2001). Several studies have also suggested that 
proteins involved in ubiquitylation of transcription factors or histones are crucial 
parts of preinitiation complexes and of the RNA polII holoenzyme, further 
implying a role of ubiquitylation in regulation of the transcription (Pham and 
Sauer, 2000, Chi et al., 2001). Recent evidence suggests that ubiquitylation and 
proteasomal subunits can also have a non-proteolytic role in RNA PolII 
transcriptional initiation and elongation. The later has been proposed to act  as 
"remodeling factors" as has been suggested for the APIS (AAA proteins 
independent of 20S) complex of AAA ATPases of the 19S regulatory subunit of 
the 26S proteasome, which have been shown to bound directly with promoters in 
yeast (Ferdous et al., 2001, Gonzalez et al., 2002), for review see (Conaway et al., 
2002, Ottosen et al., 2002).  
 
  
The oncoprotein c-Myc  
The c-Myc protein is a transcription factor of the basic helix-loop-helix-leucin 
zipper (bHLH Zip) family that was discovered more than two decades ago. 
Originally c-Myc was identified as cellular homologue to the viral oncogene (v-
Myc), which induces myeloid leukemia, sarcomas, liver, kidney and other type of 
tumors in chickens. (Gonda et al., 1982). It was also observed that c-Myc was 
activated by translocation in human Burkitt’s lymphoma, murine plasmocytoma 
and rat immunocytoma (Spencer et al., 1990, Spencer et al., 1992). 
The members of the Myc oncogene family involved in human cancer include c-
Myc, N-Myc and L-Myc, have all been shown to promote proliferation, growth, 
apoptosis and to inhibit terminal differentiation (Grandori et al., 2000). Several 
studies have also suggested that c-Myc plays an important role in embryonic 
growth and development. (Dang et al., 1999, Levens, 2002). c-Myc is expressed at 
very low level in quiescent G0 cells but rapidly induced in response to various 
mitogenic signals or stimuli, and expressed continually in cycling cells (Oster et 
al., 2002). 
The molecular function of Myc was still unclear until 1989 when Murre et al 
demonstrated that Myc belongs to the bHLHZip family of transcription factors and 
Blackwell et al the year after identified the E-box (CACGTG) as a six base pair 
core of DNA binding motif of Myc (Murre et al., 1989, Blackwell et al., 1990). 
The identification of Myc binding site was quickly followed by the landmark 
discovery of the Myc bHLHZip partner protein Max and its requirement for Myc 
DNA binding activity in vitro and in vivo. These findings established the function 
of c-Myc as a transcription regulator (Blackwood and Eisenman, 1991, 
Blackwood et al., 1992, Prendergast and Ziff, 1992).  
 
 
 
 
Figure 4: Schematic illustration of c-Myc, Max and Mad Structure. 
Transactivation domain, TAD. MBI and MBII conserved homology regions. Nuclear 
localization signal, NLS. Basic-helix-loop-helix/leucine zipper region, bHLHZip. Sin3 
interaction domain SID.                                           
 
Myc structure and Myc/Max/ Mad network 
The Myc family genes are conserved in organisms from sea urchin and Drosophila 
to humans. The vertebrate c-myc genes consist of three exons including noncoding 
exon 1 which functions as a target site for several transcription factors, whereas 
exon 2 and 3 contain the coding region for the major Myc proteins Two promoters 
1  end  of  located  at  the  5`-  exon  account                                                                    
for 90-95% of the transcripts and give rise to mRNAs of about 2,2 and 2,4 kb. 
From these mRNAs c-Myc proteins of about 64 and 67 kDa are translated. Several 
functional domains of the resulting Myc proteins have been mapped to the amino 
terminal, central and carboxy-terminal region of the protein (Watson et al., 1983, 
DePinho et al., 1987, Katoh et al., 1988, Sawai et al., 1990 ).  
The N-terminus of c-Myc (1-143) harbours the transactivation domain (TAD) 
which is involved in Myc-regulated transcription, and contains two highly 
conserved regions called as Myc box 1 and 2 (MBI and MBII). Different studies 
have suggested that MBII is essential for all biological functions of Myc. 
Significantly both MBI and MBII are required for cell transformation. (Chang et 
al., 2000, Grandori et al., 2000). 
The C-terminal domain of Myc contains the basic region/helix-loop-helix/leucine 
zipper (bHLHZip) motif, which is required for all known biological functions of 
the Myc protein. The bHLHZip domain mediates dimerization with Max, and 
binding to the E-box, DNA recognition sequence (See figure 4).   
The central region contains a nuclear localization signal (NLS) which has been 
suggested to be important for import into the nucleus and a central acidic domain 
which includes several phosphorylation sites with unclear function. (Luscher et al., 
1989, Hagiwara et al., 1992). 
In addition to Myc, Max can also form dimers with the Mad family of bHLHZip 
proteins, including Mad1, Mxi1 (Mad2), Mad3, Mad4, and with Mnt which all are 
Myc antagonists and mediate transcription silencing or repression by binding to 
similar if not identical E-boxes as Myc:Max. Indeed, Myc and Mad/Mnt proteins 
compete for Max binding within the Myc-Max-Mad network. In contrast to c-
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Myc, the expression levels of several Mad genes increase during differentiation, 
(Ayer et al., 1993, Amati and Land, 1994, Foley and Eisenman, 1999). In addition 
to Mad and Mnt proteins, Max can also interact with Mga (Billin et al., 1999, 
Hurlin et al., 1999, Sommer et al., 1999, Meroni et al., 2000). 
The Mad proteins and Mnt contain a Sin3-interacting domain (SID) motif, which 
recruits the adaptor protein, Sin3 which is part of transcriptional complexes 
containing HDAC1/2 (histone deacetylases), (Ayer et al., 1995, Alland et al., 
1997, Heinzel et al., 1997). In contrast to Mad, Myc activates transcription 
through interaction with the coactivator Transformation-transactivation
 domain-
Associated Protein (TRRAP) through the TAD of Myc, involving MBII. TRRAP 
associates with several histone acetyltransferase complexes containing the HATs 
GCN5, PCAF or Tip60 (McMahon et al., 2000, Fuchs et al., 2001, Flinn et al., 
2002, Fernandez et al., 2003), and has therefore been suggested to act as an 
adaptor recruiting different HAT activities to Myc target promoters during 
transcriptional activation (Liu et al., 2003). The ATPase domain-containing 
proteins, TIP48 and TIP49 have also been found to interact with the TAD of Myc 
and the ATPase activity of Tip49 has been shown to be important for c-Myc 
oncogenic activity. TIP48 and TIP49 have also shown to interact with BAF53 
which is one component of the GCN5-containing so called STAGA complex. In 
addition, GCN5, TIP48, TIP49, and BAF53 proteins have shown to play
 essential 
roles in Myc-dependent cell transformation. And all are part of a variety of both 
shared
 and distinct multiprotein complexes involved in regulation
 of chromatin 
structure via either ATP-dependent nucleosome remodeling (e.g. BAF53-
containing SWI/SNF-like complexes) or
  histone acetylation. (McMahon et al., 
1998, Park et al., 2001, Nikiforov et al., 2002, Frank et al., 2003). 
In addition to activation, c-Myc is also able to repress the transcription. The HLH-
domain of c-Myc can interact with Miz1 (Myc-interacting Zinc finger protein1) 
(Adhikary et al., 2003, Wu et al., 2003), and recent evidence suggest that this 
interaction plays an important role in c-Myc-mediated transcriptional repression of 
promoters of several of cell cycle related genes, such as p15
Ink4α, p21
Cip1 and 
p27
Kip1. Miz1 was found to upregulate the expression of these genes by binding to 
initiator (Inr) like elements at their promoters. However Myc can be antagonized 
by this process forming complexes with Miz1, and thereby inhibits Miz1-mediated 
transcriptional activation of these genes (Staller et al., 2001, Adhikary et al., 2003, 
Kime and Wright, 2003, Wanzel et al., 2003, Wu et al., 2003). 
 
Biological activities of Myc 
Several studies in the last two decades have shown that Myc is a multifunctional 
protein that plays a critical role in regulation of numerous cellular processes 
including proliferation, differentiation, apoptosis and tumorigenesis. Myc is able 
to control all these biological activities through turning on and off the transcription 
of Myc target genes. Therefore, the target genes link Myc to its biological 
activities. In the following section the evidence for Myc’s role in both normal and 
abnormal cellular activities is described see Figure 5. Several hundred of Myc 
target genes have been identified during last years, genes that are involved in 
almost all biological activities, such as cell cycle, transformation,  Signals 
Myc
Cell cycle/growth Apoptosis
Angiogenesis Differentiation
  Genomic    Transformation   Instability 
 
 
Figure 5: Myc biological activities. In response to extra cellular signals Myc can regulate 
different target genes in different process  
                                        
-differentiation, metabolism, apoptosis and DNA-repair (James and Eisenman, 
2002, Fernandez et al., 2003).  
 
Myc and cell cycle/ growth 
The Myc family of transcription factors has been implicated in cell growth and cell 
cycle control and Myc:Max DNA binding sites are present in the promoters of 
several growth and cell cycle regulatory genes. Numerous of studies have shown 
an essential role of Myc in the transition from G0/G1 to the G1/S phase of the cell 
cycle, expression of the myc gene is rapidly induced. Upon mitogenic stimulation 
such as through plated-derived growth factor (PDGF). Activation of Myc 
expression through mitogenic signaling or through oncogenic events, leads to 
direct or indirect activation or repression of several genes involved in the cell 
cycle regulation. Myc activation in quiescent fibroblasts has shown to increase the 
activation of CycD/CDK4/6 and CycE/CDK2 while inactivation of Myc can 
results in repression of CDK4/6 kinase activity (Mateyak et al., 1999). The 
activation of these CDK complexes by Myc can occur through different 
mechanisms. The phosphatase cdc25A, which activates both CDK2 and CDK4 by 
removing inhibitory phosphorylations, (see above) is target gene activated by c-
Myc (Galaktionov et al., 1996, Amati et al., 1998). Myc also directly activates the 
CycD1 and CDK4 genes through E-boxes in their promoter regions. The increased 
expression of CycD1 leads to sequestration of the CDK inhibitor p27
Kip1into 
CycD/CDK4/6 complexes, resulting in formation of active CycE/CDK2 through 
p27
Kip1 release (Coller et al., 2000, Hermeking et al., 2000, Luscher, 2001). 
Further, phosphorylation of p27
KIP1 by CycE/CDK2 targets p27
KIP1 for degradation 
through ubiquitin-proteasome pathway by interaction with ubiquitin-ligase 
complex SCF-Skp2, thereby generate a positive autoregulation loop which further 
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activate CycE/CDK2. It was recently shown that Cul1, which is an important 
component of SCF-Skp2, is another downstream target gene for Myc, (O'Hagan et 
al., 2000). 
Inhibition of p27
 KIP1 does not appear to be the only rate limiting cell cycle target 
of Myc since p21
CIP1 / p27
KIP1-deficient fibroblasts are still sensitive to Myc with 
respect to CycE/CDK2 activation. In contrast, deletion of the pocket proteins 
p107, p130 and Rb in mice are insensitive to c-Myc, indicating that activation of 
CycE/CDK2 by Myc, is directly dependent on Rb family members, (Berns et al., 
2000, Martins and Berns, 2002). As mentioned above pRb and other pocket 
proteins are targets for both CycD/CDK4 and CycE/CDK2 complexes, which are 
direct and indirectly activated by Myc.  
This fits with observations suggesting that Myc overexpression induces the 
activity of the E2F/DP family of the transcription factors since phosphorylation of 
Rb by CycD/CDK4/6 results in activation of E2F/DP by releasing Rb from the 
complex (Jansen-Durr et al., 1993, Leone et al., 1997). This allows activation of 
E2F target genes involving DNA replication as described above. In addition, the 
E2F family genes (including E2F1, 2 and 3) have also all been shown to be Myc 
target genes (Leone et al., 1997). c-Myc may also have a role in other phase of the 
cell cycle than G1 as it has been shown that c-Myc null rat fibroblasts have 
prolonged both G1 and G2 phases of the cell cycle, (Mateyak et al., 1997). In 
drosophila, loss of the c-myc homolog dMyc leads to retarded growth and reduced 
cell size, and overexpression of dMyc resulted in larger cells without a significant 
changes in cell cycle although the G1-phase become shorter (Johnston and 
Gallant, 2002). This suggests that c-Myc has a role in the “growth” aspect of cell 
proliferation, which fits with observations that numerous Myc target genes are 
involved in macromolecular synthesis and metabolism.   
 
Myc inhibits cell differentiation  
In addition to its stimulation of cell proliferation Myc appears to actively repress 
differentiation and cell cycle arrest programs. Many studies have shown a 
significant role of the Myc:Mad:Max network in regulating the switch between 
cell growth and differentiation, (Foley and Eisenman, 1999, Grandori et al., 2000). 
mad and myc genes are inversely expressed during differentiation, when many 
mad genes are upregulated in response to differentiation signals whereas myc 
family genes are downregulated. Indeed down regulation of Myc is one of the 
earliest events in response to negative growth regulatory signals and is important 
for cells to exit cell cycle and initiate differentiation processes. 
(Chin et al., 1996, Luscher and Larsson, 1999). The differentiation process is 
usually accompanied by cell arrest, and one possibility is that Mad promotes 
terminal differentiation through transcriptional repression of genes favoring cell 
cycle progression while Myc inhibits differentiation by maintaining the expression 
of the same or similar sites of genes. Foe instance, during myeloid differentiation 
of HL-60 cells, the downregulated expression of cycD2 and hTERT Myc target 
genes was proceeded was proceed by a switch of promoter occupancy from Myc 
to Mad as demonstrated by CHIP analysis (Bouchard et al., 2001, Xu et al., 2001). 
It is also probable that suppression of specific genes that critically regulate growth 
arrest and differentiation by Myc, such as p21
Cip1, p27
Kip1 (Rama et al., 2003) and 
Gadd45, (Amundson et al., 1998), and Gas1, (Lee et al., 1997), ensure that cells   27 
are unable to exit the cell cycle to enter a differentiation pathway (Claassen and 
Hann, 1999). In support of this hypothesis, enforced of the transcription factor 
C/EBP-α  which activates both the p21
Cip1 and Gadd45 genes, can overcome the 
inhibition of differentiation by Myc (Freytag, 1988).  
 
Myc and apoptosis 
Apoptosis is an important safeguard that protects the organism from cancer by 
eliminating tumor cells. Studies during the last decade have shown that many 
oncoproteins that stimulates cell proliferation such as c-Myc and E1A can also 
induce apoptosis. Early studies have shown that deregulation of c-Myc expression 
induced apoptosis upon serum deprivation (Evan et al., 1992) or by interleukin-3 
deprivation (Askew et al., 1991). Myc has also been shown to sensitize cells to 
pro-apoptotic stimuli through receptors such as CD95, (Hueber et al., 1997), TNF, 
(Klefstrom et al., 1994), and TRAIL, (Lutz et al., 2002). Myc expression has also 
shown to induce the apoptosis through directly activation of p53 by stimulating 
expression of ARF, which act as potent tumor suppressors by targeting pRb and 
p53 function through stabilization of p53 by MDM2 inhibition
  (Zindy et al., 
1998). The mechanism by which Myc induces p53-independent apoptos has not 
been fully clarified. Myc target genes such as ODC, lactat dehydrogenase A 
(LDH-A) and cdc25A (Hoffman and Liebermann, 1998, Haggerty et al., 2003, 
Nilsson et al., 2004) has been suggested to play a role in apoptosis. A role in Myc 
in activation of the pro-apoptotic factor Bax has been shown by analysis of c-Myc 
null Rat-1 fibroblast cells, were Bax is not activated and cytochrome C is not 
released by apoptotic stimuli, (Soucie et al., 2001). In addition, Myc has also 
shown to repress the anti-apoptotic genes such as Bcl2 and Bcl-x, which reside in 
the outer mitochondria membrane and suppress apoptosis by blocking the 
membrane permeabilization (MOMP) which is necessary for cytochrome C release 
(Martinou and Green, 2001). Stimulation of apoptosis after serum starvation or by 
deregulated Myc expression has also been suggested to occur through induced 
accumulation of reactive oxygen species (ROS) through inhibition of NF-κB 
activity by E2F binding, (Tanaka et al., 2002, Vafa et al., 2002).  
The phosphorylation sites in TAD of Myc have also been suggested to contribute 
to Myc-induced apoptosis. Mutation of Ser-71 has reported to result in reduced 
levels of cytochrome C release from mitochondria, which is one of the 
characterizes of apoptosis stimulated by Myc, further the antiapoptotic survival 
factor insulin-like growth factor 1 was reported to suppress phosphorylation of 
Thr-58, suggesting that the TAD is a direct target of survival signals (Chang et al., 
2000). The exact function of these phosphorylation sites in apoptosis however 
remains unclear. 
 
Myc participation in immortalization, genetic instability and angiogenesis 
Myc has also been implicated in the process of cell immortalization. The process 
of immortality and apoptosis/survival seem to be interconnected, based on results 
showing that overexpression Myc can promote immortality provided that the cells 
are rescued from cell death, through loss of p53 or Arf (Eischen et al., 1999). In 
human cells immortality requires upregulation and constitutive activation of 
telomerase (hTERT), has been shown to be a Myc target gene in variety of human 
cell types (Wu et al., 1999, Xu et al., 2001). Like for many, but apparently not all   28
Myc target genes, Myc induction of TERT is dependent on Myc interaction with 
TRRAP (Nikiforov et al., 2002). 
As mentioned above, cancer cells are characterized by chromosomal aberration, 
like gene amplifications and translocations, a phenomenon that is referred to as 
genomic instability. Abnormal Myc expression has been suggested to promote the 
induction of genomic instability (Felsher and Bishop, 1999, Vafa et al., 2002) by 
allowing cells to proliferate continuously despite DNA damage or mutations. 
Replication of damaged DNA correlates with loss of p53 activity, which regulates 
cell death in response to DNA damage (Yin et al., 1999, Pelengaris et al., 2002).  
In order for tumors to survive and grow, cancer cells must be able to stimulate the 
outgrowth of blood vessels around the tumor to provide the tumor cells with 
oxygen and nutrients. Vascular endothelial growth factor (VEGF) and fibroblast 
growth factor-2 (FGF-2) are two factors involved in stimulation of angiogenesis 
(Yancopoulos et al., 2000). Myc has been shown to positively regulate 
angiogenesis through induction of VEGF (Brandvold et al., 2000, Breit et al., 
2000, Pelengaris et al., 2002). Myc can also repress the expression of the 
angiogenesis inhibitor thrombospondin-1, further suggesting that Myc act as a 
positive and negative regulator of genes involved in angiogenesis (Janz et al., 
2000, Ngo et al., 2000). 
 
Posttranslational regulation of Myc 
The expression of the c-myc gene is tightly controlled by growth and 
differentiation signals, but relatively little is known about and posttranslational 
regulation of Myc. 
Myc is a phospho-protein and can be phosphorylated at numerous serine and 
threonine sites, including Thr-58 and Ser-62 in MB I, Ser-71 and Ser-82 between 
MBI and MBII and Ser164 upstream MBII in the TAD. The central acid region of 
c-Myc also contains a cluster of five in vivo phosphorylation sites within residues 
240-262. Another group of in vivo phosphorylation sites residue immediately 
upstream of the DNA binding basic region at Ser-293 and Thr-343, Ser-344, 
Ser347 and Ser-348 in BR. Ser-373, Thr-358 and Thr-400 in HLH domain 
(Luscher et al., 1989, Henriksson et al., 1993, Lutterbach and Hann, 1994, 
Lutterbach and Hann, 1997, Huang et al., 2004). However the role of most of 
these modifications remains unclear. Mutation at Thr-58 or other mutations in the 
vicinity which abolish phosphorylation at this site has found in more than 50% of 
BL. Glycogen synthase kinase
 3 (GSK-3) has been reported to phosphorylate Thr-
58 in vitro and in vivo and is dependent on prior phosphorylation of Ser-62 
residue (Henriksson et al., 1993, Lutterbach and Hann, 1994, Pulverer et al., 1994, 
Gregory et al., 2003). In addition, mutation at Thr-58 has shown to enhance c-Myc 
activity in cellular transformation assay while mutation at Ser-62 severely 
inhibited transformation (Henriksson et al., 1993, Pulverer et al., 1994, Chang et 
al., 2000). Other studies have suggested that mitogen-activated protein kinase 
(MAPK) and unidentified CDK could be involved in the phosphorylation of Ser-
62(Lutterbach and Hann, 1999). Noguchi et al reported that c-Jun N-terminal 
kinase (JNK) could phosphorylate Ser-62 and Ser-71, (Noguchi et al., 1999). 
Other studies have suggested that Ser261 and Ser263 in the central acid region 
phosphorylates by CKII (Luscher et al., 1989). Recently, it was reported that 
phosphorylation of Myc at Thr-358, Ser-373 and Thr-400 by Pak2 in response to   29 
stress related signals reduces Myc DNA binding, and phosphorylation of Ser-373 
and Thr-400 blocks Myc: Max dimerization. (Huang et al., 2004). Myc 
phosphorylation has also been suggested to play a role in apoptosis (Noguchi et 
al., 1999, Chang et al., 2000, Noguchi et al., 2001). (Noguchi et al) showed that 
activation of c-Jun N-terminal kinase (JNK) by apoptotic stimuli led to 
phosphorylation Ser-62 and Ser-71 of Myc while mutations of these residues made 
Myc unable to stimulate apoptosis (Noguchi et al., 1999). The authors suggested 
that phosphorylation of Ser-71 was somehow involved in cytochrome C release 
which stimulates apoptosis through caspase activation (Chang et al., 2000).  
Myc has a very short-life of 25-30 minutes. We and other have shown that 
destruction of Myc is mediated by ubiquitin-proteasome pathway, and the 
mutation of Thr-58 and other hotspot mutations in BL lead to Myc stabilization. 
This suggest that phosphorylation of Thr-58 is a signal that directs Myc for 
proteasomal degradation further (Sears et al) have suggested that phosphorylation 
at Ser 62 is involved in Myc turnover by stabilizing c-Myc, in response to Ras 
signaling. In addition to phosphorylation, Myc has also shown to be alternatively 
modified at Thr-58 by O-GlcNAC glycosylation, suggesting additional 
modification of Myc. Glycosylation of Thr-58 has been suggested to be involved 
in stability and subcellular localization of Myc (Kamemura et al., 2002). In 
addition to above mentioned modifications the HAT CBP was reported to 
acetylate c-Myc in vitro and coexpression of Myc with CBP stimulated acetylation 
of Myc in vivo. This modification was shown to decrease ubiquitylation and 
stabilization of Myc (Vervoorts et al., 2003). Taken together it seems that multiple 
mechanisms exist to regulate Myc protein activity and stability.  
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Aims of the present investigation 
 
The general objective of this thesis was to gain further insight into post-
translational regulation of Myc and thereby make a contribution to the 
development of better treatment strategies for tumor with deregulated Myc. The 
thesis can be divided into two parts. The aims of the first part including papers I 
and II, was to increase the knowledge of Myc degradation pathways and to 
identify components specifically participating in Myc turnover. The aim of the 
second part containing paper III and IV was to clarify the mechanisms by which 
IFN-γ regulates Myc function posttranslationally. 
 
 
The specific aims of this work were: 
 
1-To clarify whether Myc “hotspot” mutation in BL play a role in Myc turnover. 
 
2- To identify specific SCF-E3 ubiquitin ligase complexes involved in the 
ubiquitylation of Myc and to clarify their role in Myc function. 
 
3- To elucidate whether the previously describe IFN-γ-induced anti-Myc activity 
directly affects on Myc function (with response to Myc-induces transcription, 
DNA binding etc) as a transcription factors. 
 
4- To clarify whether IFN-γ induces ubiquitin/proteasomal degradation of Myc. 
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Results and discussion 
 
c-Myc hot spot mutations in lymphomas result in inefficient 
ubiquitylation and decreased proteasome-mediated turnover 
(paper I) 
 
The objective of this work was to investigate the consequence of the frequently 
found hotspot mutations in c-Myc in Burkitt’s lymphoma. In addition to the 
obligatory translocation between c-Myc and either of the Ig-loci in Burkitt’s 
lymphoma, mutations in the coding region of Myc in particular of Thr-58 and Pro-
57 was frequently found in both in primary
 tumors and in cell lines derived from 
lymphomas Burkitt’s (Bhatia et al., 1993, Yano et al., 1993, Axelson et al., 1995). 
Furthermore the Thr-58 be mutation occurs in all v-Myc proteins, and has been 
shown to increase the transforming potential of Myc. Thr-58 is an in vivo 
phosphorylation site and has been reported to be  phosphorylated in vitro and in 
vivo by Glycogen synthase kinase
 3 (GSK-3), while proline at position 57 has 
been shown to be a prerequisite for Thr-58 phosphorylation by GSK3 (Bousset et 
al., 1993, Pulverer et al., 1994, Lutterbach, 1994 #47, Gregory, 2003 #72). 
 
Decreased turnover of c-Myc mutated at Thr58 or Pro57 in Burkitt's lymphoma 
cells  
 
The turnover of many transcription factors and other regulatory proteins is often 
controlled by phosphorylation or other modifications. We therefore hypothesized 
that the Thr-58 and Pro-57 hotspot mutations might play a role in Myc turnover. 
We first investigated the turnover of c-Myc in the Burkitt's lymphoma
 (BL) cell 
lines Daudi, Jijoye and BJAB (with wild type [wt] c-myc), Raji, and CA46 (with 
c-myc
 mutations, including Thr58 and Pro57), Mutu and
 Rael, both with a single 
mutation of Thr58 and finally ST486 with mutation
 in Pro57.  Cycloheximide 
chase analysis showed that Myc half-life was fourfold longer in Burkitt's 
lymphoma containing Myc with mutations in Thr-58 or Pro-57 compared to 
wildtype Myc. Simultaneous measuring of the half-life of endogenous c-and 
exogenous v-Myc in v-Myc transformed monocytic U937 cells, showed that c-
Myc turned over rapidly (around 30 minutes), while v-Myc which carries a Thr-58 
mutation turned over at a much slower rate (half-life approximately 120 minutes) 
in the same cells. Taken together these results demonstrated that Thr-58 and Pro-
57 mutations led to Myc stabilization. 
 
The role of Thr-58 in Myc ubiquitin-proteasome mediated degradation 
 
Previous work had implicated the ubiquitin-mediated proteolytic system in the 
turnover of short-lived transcription factors and cell cycle regulatory proteins 
(Weissman, 2001). Ubiquitylation of c- and N-Myc in vitro was reported 
previously (Ciechanover et al., 1991) but this had not been demonstrated in vivo. 
We therefore investigated the effects of proteasome inhibitors on c-Myc stability   32
in BL and in v-Myc-transformed U937 cells. We observed that c-Myc was 
noticeably stabilized and v-Myc was somewhat further stabilized by several of 
proteasome inhibitors but not by other protease inhibitors. The observation that 
Myc is degraded by the ubiquitin-proteasome pathway prompted us to investigate 
whether Thr-58 and Pro-57 might be involved in this process. A pulse chase 
experiment revealed that the proteasome inhibitor MG132 stabilized wt
 c-Myc in 
Daudi significantly but had less effect on the already stabilized Myc in CA46 
cells. Together these results suggested
 that Thr-58 and Pro-57 mutations led to 
impaired proteasome-mediated turnover. 
Proteasome-mediated degradation is dependent on ubiquitylation of the target 
protein, (Hershko and Ciechanover, 1998). We therefore next examined whether 
Thr-58 mutation could interfere with Myc ubiquitylation, using in vivo 
ubiquitylation assays. U2OS cells were cotransfected with wild type or T58A c-
Myc together with an expression vector containing His-tagged ubiquitin. Western 
blot analysis showed that cotransfection of wt-c-Myc together with His-Ub 
generated a strong smear of ubiquitylated Myc. The T58A Myc mutant was also 
ubiquitylated but to a reduced extent in comparison with wt Myc. These 
observations thus indicate that Myc ubiquitylation is regulated by Thr-58 
phosphorylation. However, ubiquitylation did not seem to be entirely dependent 
on Thr58 since the T58A mutant was still ubiquitylated. In conclusion the 
phosphorylation of Thr-58 seems to have an important role in regulation of c-Myc 
ubiquitin-proteasome mediated degradation. 
Our observations within this work is in part in agreement with the reports by 
(Salghetti et al., 1999, Gregory and Hann, 2000, Sears and Nevins, 2002), which 
reports demonstrated that Thr-58 mutation led to c-Myc stabilization. Despite this, 
Gregory et al argued that c-Myc stabilization in BL might was due to some 
disorder of the ubiquitin-proteasome machinery in these cells rather than the c-
Myc mutation, since wt c-Myc transfected into CA46 BL cells was also stabilized. 
This conclusion disagrees with our results since we have demonstrated that 
transfected wt c-Myc turned over rapidly while endogenous Myc with Thr-58 
mutation was stabilized in the same Raji BL cells. The reason for this discrepancy 
is unclear, but might indicate that additional oncogenic events affecting the 
ubiquitin-proteasome pathway contributes to further Myc stabilization in some BL 
but not in others. We find it unlikely that this is a general explanation for the 
stabilization of c-Myc in BL, since independent reports from at least three groups 
found that mutation in Thr-58 stabilize Myc also in other cells than BL. We have 
also found that too high overexpression of wt c-Myc often results in stabilization, 
and consequently the amount of transfected Myc must be carefully titrated. 
Our results suggest that phosphorylation of Thr-58 trigger ubiquitin-mediated 
degradation. We hypothesize that such phosphorylation site could be recognized 
by E3-ligase involved in Myc degradation.  However, we still don’t have evidence 
demonstrating that Thr-58 is directly involved ubiquitylation and degradation of 
Myc. An alternative hypothesis is that phosphorylation of Thr-58 is involved in 
subcellular localization of Myc which in turn affects its ubiquitylation and 
degradation. GSK3 which phosphorylates Myc-Thr-58 (Henriksson et al., 1993, 
Lutterbach and Hann, 1994, Pulverer et al., 1994, Gregory et al., 2003) has been 
shown to regulate both subcellular localization and degradation of CycD1 via Thr-
286 phosphorylation. CycD1 mutated at Thr-286 remained in the nucleus and was   33 
stabilized (Diehl et al., 1998). It is possibly that GSK3 could regulate c-Myc 
through a similar mechanism.  
In agreement with our observation, Salghetti et al showed that Thr-58 mutation 
and deletion of the first 128 residues in N-terminal stabilized Myc. Further, (Flinn 
et al) (Flinn et al., 1998) showed that deletion of MBI increased the half-life of c-
Myc in agreement with our observation (paper II) and (data not shown). In 
contrast, Gregory et al (Gregory and Hann, 2000) showed that c-MycS, which lack 
the N-terminal 100  amino
  acids of c-Myc, is rapidly degraded and was highly 
ubiquitylated. This result is contradictory to results from Flinn, Salghetti and our 
work because c-MycS have also deleted MBI. Contradictory like this are discussed 
further below.  
In addition to MBI, several groups has shown that deletion of MBII (Flinn et al., 
1998, Salghetti et al., 1999, von der Lehr et al., 2003) or deletion of the first 158 
aa N-terminal sequences, (Gregory and Hann, 2000) stabilized Myc (see 
discussion below). 
  In addition to MBI and MBII. (Gregory et al)(Gregory and Hann, 2000) 
suggested that the centrally located region, amino acids 226-270, was necessary 
for rapid c-Myc degradation, but not for ubiquitylation. Another report suggested 
that the region 127-189 is essential for TNF-induced Myc stabilization (Alarcon-
Vargas et al., 2002). Salghetti et al has also suggested that deletion in Miz1 
binding region (within HLH-motif) in the C-terminus of c-Myc reduced Myc 
stability, while overexpression of Miz1 stabilized c-Myc (Salghetti et al., 1999). 
Herbst et al has recently identified a second element (D-element) which is 
centrally located in c-Myc. Deletion of the D-element stabilized Myc without 
affecting its ubiquitylation (Herbst et al., 2004). Taken together all these 
observations suggested that several different regions of Myc could be 
independently involved in Myc stabilization/degradation. 
The discrepancies of the different studies might be due several factors. One 
explanation is that the c-Myc mutants used were not identical. Further, deletion of 
certain regions can also have structural consequences which potentially could 
affect c-Myc stability. 
If several different regions of c-Myc is involved in regulating c-Myc stability, they 
could be of different importance in different tissue. Different cell lines used in the 
different studies can therefore lead to different conclusions.  
 
SCF-Skp2 is involved in Myc ubiquitin- proteasome mediated 
degradation and transcriptional activation (paper II) 
 
The results form paper I showed that Myc oncoprotein like many other 
transcription factors was degraded through ubiquitin-proteasome pathway. The 
ubiquitylations process requires three activities; ubiquitin activating enzyme E1, 
ubiquitin conjugating enzyme E2 and finally the ubiquitin ligase E3, (Hershko and 
Ciechanover, 1998) as described above. Since we and others had observed that 
this degradation pathway seemed to be phosphorylation dependent and an 
increasing amount of regulatory factors were reported to bind to SCF-complexes 
prior to their degradation we aimed for identifying a specific E3 ligase, possibly of 
SCF nature, for c-Myc.  
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c-Myc binds to the F-box-protein Skp2 in vivo and in vitro 
  
To establish whether c-Myc does interact with a SCF-complex we initiated our 
work by investigating if c-Myc can interact with Cul1, which is one of the 
common components of SCF complexes. Cotransfection of c-Myc and Cul1 into 
Cos7 cells followed by immunoprecipitation and western blot analysis 
demonstrated that c-Myc interact with Cul1 in vivo, indicating that Myc can 
interact with SCF-complexes, possibly through endogenous bridging F-box 
proteins. Accordingly, we tested several known F-box proteins belonging to 
different classes to clarify whether any of them could interact with c-Myc. We 
found that Skp2 strongly and another member of the LRR-family, Fb15 weakly 
interacted with c-Myc in vivo after cotransfection while other F-box proteins did 
not. Further, we found that overexpression of Skp2 strongly promoted c-Myc 
degradation in contrast to other F-box proteins showed only minor effects. 
Therefore we concentrated our work on Skp2, and could demonstrate an 
interaction between Myc and endogenous Skp2 in HeLa cell extracts and also in 
vitro by GST-pulldown experiments. In order to identify the c-Myc regions that 
interact with Skp2, we constructed a panel of deletion mutants which used 
together with Skp2 cotransfection. We found that both MBII and the bHLHZip 
domain were essential for Skp2 interaction. These observations were also 
confirmed by in vitro GST-pulldown assays. In addition we also utilized the 
bimolecular fluorescence complementation assay (BiFC) as described by (Hu et 
al., 2002a) to study interactions between Myc and Skp2 in living cells. This 
technique is based on reconstitution of yellow fluorescent protein (YFP) from two 
non-fluorescent fragments when brought together by the association between two 
interaction partners fused to the fragments. The N-terminal (YN) and C-terminal 
(YC) fragments of YFP were fused to Skp2 and c-Myc, respectively, and 
expression vectors containing these fusion proteins were transfected into Cos7 
cells either alone or together. Through this method we found that Skp2 and c-Myc 
interacted in the nucleus. In conclusion we showed that c-Myc interacts directly 
with Skp2 in vivo and in vitro through the MBII and the bHLHZip domains and 
that this interaction occurs in nucleus.  
In agreement to our work, Kim et al has identified the same region of Myc that 
involved in Skp2 binding  
 
The role of SCF-Skp2 in c-Myc ubiquitylation and degradation 
 
To clarify whether Skp2 has any role in c-Myc degradation we attempted several 
approaches. We could first demonstrate that Skp2 promoted c-Myc degradation 
when cotransfected with Myc and Cul1. To investigate whether c-Myc 
degradation was affected in cells with compromised Skp2 activity, we utilized a 
dominant negative Skp2 mutant (Skp2∆F) which lacks the F-Box and therefore is 
not able to bind Skp1 and thereby can not recruit a SCF functional E3 ligase. 
Cycloheximide chase assays demonstrated that Skp2∆F increased c-Myc half life 
fourfold. To confirm that Skp2∆F operated as a dominant negative mutant and did 
not cause general affects on the degradation system, we first stabilized c-Myc by 
Skp2∆F and then titrates in increasing amounts of cotransfected wt-Skp2. The 
results showed that Skp2 restored c-Myc degradation further indicating that Skp2 
is participating in c-Myc degradation. We have also confirmed these results by   35 
utilizing the siRNA technique, which is based on interference of small specific 
synthetic dsRNA oligos with a particular transcribed mRNA. Skp2 siRNA 
transfection into HeLa cells showed followed cycloheximide chase analysis 
showed that Skp2 siRNA decreased Myc degradation, further demonstrating that 
Skp2 is important in c-Myc degradation. In addition to these results we also 
observed that a c-Myc mutant lacking MBII and the C-terminal and therefore is 
unable to bind Skp2 was stabilized. Taken together the results suggested that SCF
-
Skp2 has an essential role in c-Myc degradation. Since we and others had 
established that c-Myc is degraded through the ubiquitin-proteasome pathway 
(paper I) and (Flinn et al., 1998, Salghetti et al., 1999, Bahram et al., 2000, 
Gregory and Hann, 2000). We next investigated whether Skp2 participates in c-
Myc ubiquitylation, by doing an in vivo ubiquitin assay as above. We found that 
Skp2 cotransfection increased the amount of ubiquitylated c-Myc, while Skp2∆F 
overexpression strongly reduced the intensity of the polyubiquitylated detected 
smear. Further titrating in increased amounts of wt Skp2 into Skp2∆F 
cotransfected cells restored polyubiquitylation c-Myc. Taken together these 
observations suggested that Skp2 participates in c-Myc ubiquitylation.  
 
Skp2/c-Myc interaction is regulated in the cell cycle  
 
To study the biological function of c-Myc/Skp2 interaction we investigated the 
kinetics of the interaction between endogenous Skp2 and c-Myc during cell cycle 
activation and progression in peripheral blood lymphocytes (PBL). PBL cells were 
stimulated with PHA and IL-2 to become activated and to enter into the cell cycle. 
The expression of c-Myc was undetectable in resting cells, but increased strongly 
in early G1-phase and then declined starting from the G1/S-phase transition. The 
expression of Skp2 was also invisible in rested cells and gradually increased 
during late G1-phase reached a peak in at the G1/S-phase transition in agreement 
with previous reports (Carrano et al., 1999, Marti et al., 1999, Sutterluty et al., 
1999). The interaction between Skp2 and c-Myc was strongest in S-phase 
correlating with high expression of Skp2 and with increased c-Myc degradation. 
We conclude that Skp2 interact with Myc during the S-phase in normal 
lymphocytes. 
We utilized Rat1 cells containing inducible MycER construct and cotransfected 
these with Skp2 or Skp2∆F and pEGFP. The GFP-positive cells were then sorted 
by FACS. Myc-induced G1/S-phase transition upon activation of MycER by 4-
OHT was studied by cell cycle analysis using FACS. The results showed that 
cotransfection with wt Skp2 led to increased number of S-phase-cells, while 
Skp2∆F expression resulted in inhibition of c-Myc induced S-phase transition. 
This effect of Skp2 as due to indirect effects through Skp2-mediated degradation 
of the p27
Kip1, since similar results were observed in MycER-expressing p27-/- 
MEF cells. Taken together our findings suggested that Skp2 is a positive regulator 
of c-Myc-dependent S-phase entry.  
 
Skp2 promotes c-Myc induced transcription     
 
Our observation that Skp2 promotes c-Myc-induced G1/S-phase transition incited 
us to investigate whether enforced Skp2 expression had any effects on c-Myc-
induced transcription of its target genes. We therefore examined the effect of Skp2   36
on c-Myc-activated transcription from the α-prothymosin (α-ProT) promoter, a 
wellknown c-Myc target gene, in transiently cotransfection with c-Myc and a α-
ProT promoter/luciferase (Luc) reporter gene in HeLa cells. In agreement with 
previous reports (Desbarats et al., 1996) and paper III, the result showed that the 
reporter activity of the wt α-ProT promoter/reporter was induced more than 
threefold by c-Myc compared with an empty expression vector, while a α-ProT 
mutant lacking the E-boxes in the first intron of the gene was not activated by 
Myc. Surprisingly, transfection with Skp2 alone also induced the reporter activity 
in an E-box dependent manner. The α-ProT-E-boxes have been shown to be c-
Myc specific (Desbarats et al., 1996), indicating that the effect of Skp2 was 
mediated by endogenous c-Myc. In contrast, cotransfection with Skp2∆F did not 
activate the promoter activity, indicated that Skp2 stimulated transcription is 
dependent on other component in E3-ligase complex. A Myc mutant with deleted 
MBII, which can not bind TRRAP and has reduced binding to Skp2, could not 
activate the reporter. Moreover Skp2∆F had strong inhibitory effect on c-Myc-
induced activation of the transcription, whereas cotransfection with wt Skp2 
stimulated the c-Myc induced activation of the promoter. In conclusion these 
observations suggested that Skp2 is required for c-Myc induced transcription 
activation and Skp2-mediated activation of c-Myc target gene is c-Myc dependent. 
This conclusion further was strengthened by experiments in Skp2-/- and c-Myc-/- 
cells which showed that Skp2 transfection into c-Myc-/- cells and c-Myc 
transfection into Skp2-/- cells, respectively, both failed to activate the transcription 
of the α-ProT/luc promoter. We observed similar effects on α-ProT -promoter 
activity by utilizing c-Myc or Skp2 siRNA, demonstrating that Skp2 siRNA and c-
Myc siRNA reduced the promoter activity to a similar degree. We next 
investigated whether c-Myc-induced activation of endogenous target genes was 
affected by Skp2 or its mutant. The results showed that Myc activation by 4-OHT  
in MycER expressing p27-/- MEF cells resulted in threefold increased mRNA 
expression of  ODC and CycD Myc target gene as previously reported (Bouchard 
et al., 2001, Frank et al., 2001, Haggerty et al., 2003) whereas the Skp2∆F mutant 
inhibited their induction by c-Myc. Taken together these results suggested that 
Skp2 and c-Myc collaborate directly or indirectly to activate the transcription of c-
Myc target genes and raises the question whether Skp2 act as coactivator for c-
Myc in transcriptional activation. To examine this hypothesis we investigated 
whether Skp2 is also associated with c-Myc at the CycD2 promoter in vivo 
utilizing chromatin immunoprecipitation (CHIP) assays. Our results showed as 
expected that c-Myc and Max were present at the CycD2 promoter. Interestingly, 
we also found Skp2 and Cul1 associated to the E-box region of CycD2 promoter. 
Although both Skp2 and c-Myc interacted with the CycD2 promoter in Rat1 
myc+/+ cells, neither Skp2 nor c-Myc was observed at the CycD2 promoter in 
Rat1 myc-/- cells. This result suggested that Skp2 requirement to the CycD2 
promoter required c-Myc. We further investigated whether ubiquitylated proteins 
and proteasome subunits could be detected at the promoter. Indeed, we found that 
the Sug1, Rpt3, Rpn7 components of the regulatory 19S subunit of the proteasome 
and α 2 subunit of the 20S proteasome as well as ubiquitylated proteins bound to 
CycD2 promoter. This observation suggested that Skp2, ubiquitylated proteins and 
several proteasome subunits is associated to CycD2 promoter region in a c-Myc 
dependent manner.   37 
 
In this paper we provide evidence that Skp2 a subunit of an E3 ubiquitin ligase 
complex is required for ubiquitylation and degradation for c-Myc. We 
demonstrated that Skp2/Myc interaction was dependent on two conserved regions, 
MBII and HLH-Zip. Both MBII and bHLHZip are essential for Myc function. The 
bHLHZip is within DNA binding domain of Myc and MBII is an important 
sequence for recruitment of the transcription coactivator TRRAP and for most 
biological activities of Myc protein. Surprisingly, Skp2 did not require MBI for 
Myc binding, and Thr-58 or Ser-62 did not seem to be involved in Myc Skp2 
binding.  Furthermore the absence of phosphorylation sites in the Skp2-binding 
region of Myc suggests that Myc and Skp2 interact in phosphorylation 
independent manner in contrast to other substrate-SCF interaction. We have also 
showed that Skp2 interact with Myc in vivo and induces its degradation and 
ubiquitylation, and this interaction seems to be direct since it was also shown in 
vitro. We have not however been able to demonstrate Skp2-dependent 
ubiquitylation and degradation of Myc in vitro, and therefore we can not exclude 
other E3 ligase mediated Myc ubiquitylation. Our observations also do not exclude 
other pathways of c-Myc degradation independent of Skp2 in different cell types 
or in response to different signals.   
Our result showed that Myc interact with Skp2 in late G1/S-phase transition 
during activation of normal lymphocytes. At this time which c-Myc is known to be 
required for S-phase entry. One possibility is that degradation is required to 
prevent constant c-Myc activity, which cans damage the cells. Surprisely our 
results demonstrate that Skp2 did not decrease Myc activity instead promotes c-
Myc-induced S-phase entry. Skp2 expression was required for Myc-induced 
transcription of its target genes. On the other hand c-Myc expression and activity 
was also required for Skp2-inducd transcription of c-Myc target genes. Our data 
suggest that Skp2 binds specifically to the Myc binding site (E-boxes) at promoter 
of the target gene, only when c-Myc is present, suggesting that Skp2 is required to 
target promoters as a coactivator of c-Myc-induced transcription. Therefore our 
data support a model of a positive relation between the activity of the transcription 
factors and their ubiquitylation, which has been suggested previously (Chi et al., 
2001, Ferdous et al., 2001, Gonzalez et al., 2002)for review see (Muratani and 
Tansey, 2003). How can E3 ligase activity stimulate c-Myc-induced transcription? 
One possibility is that SCFSkp2 induce degradation and ubiquitylation of negative 
regulators of the transcription at the promoter. This could also be part of an 
autoregulatory loop, where the Myc activator protein needs to be eliminated at 
some step in order to complete the transcription process. Another possibility is that 
c-Myc or other substrates ubiquitylated at the promoter play a nonproteolytic 
function in, for example, protein-protein interactions of importance for 
transcription, as has been suggested for Met30-directed ubiquitylation of Met4 
transcription factor (Kaiser et al., 2000). Further investigation is needed to 
determine whether degradation of c-Myc is a necessary step for activation of 
transcription. This general model has been proposed in the 'licensing' hypothesis, 
linking transcription factor activity to their destruction in order to maintain 
stringent control of transcription activation in cells. 
 
 
  
Posttranslational regulation of Myc function in response to 
phorbol ester/interferon-gamma-induced differentiation of v-
Myc-transformed U-937 monoblasts (paper III) 
 
The goal of the paper III was to clarify the mechanism behind restoration of TPA-
induced differentiation in v-Myc transformed U937 cells by IFN-γ. 
 
The expression of Mad1 is not increased in U937cells costimulated with 
TPA + IFN-γ  
 
Prior to this study, IFN-γ treatment was shown to abolish the differentiation block 
in v-Myc transformed U937 cells despite continuous expression of v-Myc (Oberg 
et al., 1991). To investigate the mechanism behind this IFN-γ activity, we first 
investigated the synthesis of Mad1, c-Myc and v-Myc, and Max proteins, during 
IFN-γ and TPA costimulation. The expression
 of Mad1 increased in response to 
TPA in parental U937 cells in agreement with previous reports, (Ayer and 
Eisenman, 1993, Larsson et al., 1994) but only transiently in v-Myc transformed 
U937 cells. IFN-γ costimulation did however not restore the expression of Mad1 
indicating that the continued
 presence of v-Myc directly or indirectly influenced 
the expression
 of Mad1. In addition, IFN-γ stimulation did not increase the mRNA 
expression of other Mad family proteins including Mxi1, Mad3, Mad4 and Mnt 
(data not shown). Further the different treatment induced some transient changes 
in the synthesis ratio of the two Max proteins p21 and p22. The expression of Max 
was not influenced by IFN-γ costimulation compared to TPA alone. In conclusion, 
Mad1 does not seem to play a major role in the IFN-γ-induced terminal 
differentiation of U937 cells. 
 
TPA + IFN-γ  inhibit Myc-regulated E-box-dependent reporter-gene activity.   
 
To address whether IFN-γ+TPA hampered the activity of Myc as transcription 
factor, we studied Myc-induced transcription in U937 cells, using the Myc-
regulated  -prothymosine CAT promoter reporter gene construct PrT-CAT and 
the mutant construct GalmE-PrT-CAT (lacking the Myc-responsive
 E-boxes in the 
first intron). In U937-neo-6 cells lacking v-myc, the stimulation with TPA, IFN-γ 
and IFN-γ+TPA all reduced the PrT-CAT activity but had little effect on GalmE-
PrT-CAT. In v-Myc transformed U937 cells, TPA did not reduce the activity of 
PrT-CAT to the same level as in U937-neo-6 cells, but IFN-γ alone and in 
particular IFN-γ+TPA efficiently inhibited the activity of the reporter activity 
suggesting that these treatments inhibit Myc-induced transcription. To further 
investigate whether IFN-γ+TPA inhibited the transactivating properties of c-Myc, 
PrT-CAT and GalmE-PrT-CAT were cotransfected with c-Myc expression vector 
(pCMV-Myc), pCMV-Myc expression stimulated PrT-CAT fourfold, but had no 
effect on GalmE-PrT-CAT activity. IFN-γ particularly IFN-γ+TPA inhibited 
pCMV-Myc-induced reporter activity, while TPA stimulation had little effect. We 
obtained similar results with an additional Myc-induced promoter/ reporter 
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construct m4mintk-Luc driven by four E-box copies upstream of a minimal-tk 
promoter. Which were stably integrated into U937-myc-6 cells.. Taken together 
these experiments suggest that IFN-γ alone and particularly IFN-γ+TPA inhibits
 
transactivation by v-Myc and c-Myc.   
 
The DNA-binding activity of Myc is decreased by IFN-γ+TPA costimulation 
 
It could be several different explanations for the IFN-γ-induced regulated 
transcription.  
To investigate whether the capacity of native Myc, Max and Mad1-complexes to 
bind specifically
 to DNA was affected in response to IFN-γ+TPA treatment, a 
solid-phase DNA binding assay was used. In this assay Myc, Mad1 and Max 
complexes were immunoprecipitated under low stringency condition from U-937 
cell extracts, after which the immunocomplexes were incubated with labeled 
oligonucleotides containing a Myc/Max binding site (CMD) or mutant variant 
(CMM). The DNA binding activity of immunoprecipitated Myc decreased after 
TPA in control U937-GTB and U937-Neo-6 cells but not in U937-myc-6 cells. In 
addition Mad1 was low in untreated but increased after stimulation of U937-GTB 
but not in U937-myc-6 cells. 
 A kinetic experiment showed that the DNA binding activity of c- and v-Myc 
declined gradually and permanently after IFN-γ +TPA treatment in U937-myc-6 
cells, but only temporarily after TPA treatment. The DNA binding activity of 
Mad1 increased only transiently in v-Myc expressing U937 cells after TPA 
stimulation and neither IFN-γ alone nor IFN-γ+TPA treatment were able to restore 
Mad1 DNA binding activity. Max DNA binding activity was not significantly 
affected in response to IFN-γ+TPA stimulation. In conclusion these results suggest 
that IFN-γ+TPA directly interfere with the DNA binding activity of Myc.  
 
IFN-γ+TPA costimulation induces Myc: Max disassociation.     
 
Since the DNA binding activity of Myc is dependent on interaction with Max, we 
next addressed whether the decline of Myc DNA binding activity in response to 
IFN-γ+TPA stimulation could be due to effects on Myc:Max complex formation 
or stability. The steady state levels of c-and v-Myc:Max or Mad:Max complexes in 
U937-myc-6 cells. were studied by coimmunoprecipitation under low stringency 
condition, followed by western blot analysis and compared to the total amount of 
these proteins in the cells. The results showed that v-Myc:Max complexes and 
total v-Myc were relatively stable during the first four hours treatment with TPA 
and IFN-γ+TPA. Thereafter the amount of v-Myc:Max complexes declined and 
reached a minimum at 24 hours. The steady state level of v-Myc was only slightly 
reduced after IFN-γ+TPA stimulation. The amount of v-Myc:Max was also 
reduced after IFN-γ alone in compared with total v-Myc, and was not  caused by 
decreased to steady state level of Max. In conclusion,
 these results suggest that an 
important consequence
 of the treatment with IFN-γ+TPA and with IFN-γ alone is 
the
 reduction in the fraction of total v-Myc and c-Myc in complex
 with
 Max. This 
suggests that the reduction of Myc-DNA binding activity and the inhibition of 
Myc-induced transcription in response to IFN-γ mentioned above is the result of 
disassociation of Myc: Max complexes.   40
 
Dephosphorylation of Myc in response to IFN-γ+TPA  
 
Destabilization of Myc: Max heterodimers could be the result of
  IFN-γ+TPA-
induced unidentified proteins competing for Myc or
 Max, or direct modification(s) 
of Myc or Max by for instance phosphorylation/ dephosph-orylation. To evaluate 
whether the overall level of phosphorylation of v-Myc and c-Myc changed in 
response to IFN-γ+TPA treatment in
 parental and v-Myc transformed U937 cells, 
aliquots of untreated and induced
  cultures were in vivo labeled with 
35S-
methionine and 
32P-orthophosphate in parallel, where after the Myc proteins were
 
immunoprecipitated and analyzed. The results showed that
 the relative intensity of 
the 
32P-labeled v-Myc and c-Myc proteins were significantly decreased compared 
to the corresponding 
35S-labeled protein level in response to IFN-γ+TPA 
costimulation, suggesting that Myc was dephosphorylated. To further study 
phosphorylation of c-and v-Myc, the proteins were also analyzed by 2D-
electrophoresis. The assays showed that IFN-γ+TPA stimulation induced a shift of 
v- and c-Myc towards the basic side of the gel. As similar shift was observed after 
phosphatase treatment, suggesting that c-and v-Myc are dephosphorylated in 
response to IFN-γ+TPA treatment. However, no effect on Max phosphorylation 
was observed after IFN-γ+TPA treatment (data not shown). We could also show 
that phosphatase treatment of Myc: Max complexes resulted in disassociation of 
Max from the complex, supporting the hypothesis that dephosphorylation of Myc 
results in destabilization of Myc: Max complexes.  
In conclusion our results in this paper suggest that IFN-γ+TPA stimulation 
restores differentiation and cell cycle arrest of v-Myc expressing U937 through 
negative regulation of Myc/DNA binding activity correlating with post-
translational modification of c-and v-Myc by dephosphorylation. 
 
 
 
Interferon-gamma inhibits CycE/Cdk2-mediated 
phosphorylation of c-Myc via p27
Kip1 resulting in increased Myc 
ubiquitylation and degradation (Paper IV) 
 
We have shown in paper III that IFN-γ +TPA antagonize Myc activity 
posttranslationally through unclear mechanisms. In this work we continue this 
study investigating the mechanisms behind IFN-γ +TPA induced inactivation and 
dephosphorylation of Myc. 
 
IFN-γ +TPA increase the rate of degradation and ubiquitylation of Myc. 
  
To address the possibility that IFN-γ-induced inactivation of Myc occurs through 
increased degradation, we first analyzed the half-life of c-and v-Myc by pulse 
chase analysis in IFN-γ +TPA costimulated or TPA–stimulated v-Myc 
transformed U937 cells. We observed that v-Myc, which is mutated at Thr58,   41 
exhibited a prolonged half life, as mentioned above see paper I (Bahram et al., 
2000). IFN-γ + TPA treatment increased both c and v-Myc turnover from 25 to 11 
and 120 to 37 minutes respectively, while TPA treatment did not affect Myc 
turnover. We conclude from these results that IFN-γ  and TPA costimulation 
increases the rate of both c-and v-Myc degradation in U937 cells and similar 
results were obtained in Colo320 carcinoma cells with c-Myc amplification. It is 
intriguing that the turnover of v-Myc also increased in response to IFN-γ + TPA 
treatment despite the Thr-58 mutation. This suggested that IFN-γ signaling utilized 
a pathway of Myc degradation distinct from the Thr-58 pathway. To investigate 
whether IFN-γ  induced Myc degradation was mediated by the Jak–Stat pathway 
we treated 2fTGH human fibrosarcoma cells or sublines of these cells lacking 
Stat1 (U3A) or lacking JAK1 (U4A) with IFN-γ.  35S-methionine pulse chase 
analysis showed that IFN-γ  treatment increased Myc turnover in parental 2FTGH 
cells but not in STAT1 deficient or Jak1 deficient cells, indicating that both 
STAT1 and JAK1 are required for IFN-γ induced Myc degradation. 
As pointed out above the ubiquitin-proteasome system is involved in Myc 
turnover, (Ciechanover et al., 1991, Bonvini et al., 1998, Flinn et al., 1998, 
Salghetti et al., 1999, Bahram et al., 2000, Gregory and Hann, 2000). To 
investigate whether IFN-γ -induced Myc degradation occurred through this 
pathway, v-Myc expressing U937 cells were treated with IFN-γ + TPA in presence 
of the proteasome inhibitor LLnL. IFN-γ-induced degradation of c- and v-Myc 
was indeed inhibited by LLnL treatment, confirming that IFN-γ-induced 
degradation occurs via the proteasome. To investigate whether IFN-γ increases 
Myc ubiquitylation, immunoprecipitated Myc was analyzed by western blot using 
ubiquitin antibodies. Our results showed that IFN-γ alone and IFN-γ + TPA but 
not TPA increased c-Myc ubiquitylation in 2fTGH cells. These results suggested 
that IFN-γ  and IFN-γ + TPA  treatment increased c-Myc ubiquitylation and 
proteasome-mediated degradation. 
 
Interferon-gamma dephosphorylates c/v-Myc at Ser-62 
 
In (paper III) we showed that IFN-γ alone and IFN-γ + TPA  treatment led to 
dephosphorylation
  of v-Myc- and c-Myc in unidentified sites (Bahram et al., 
1999). We speculated if these dephosphorylation events could be connected to the 
induced degradation of Myc. Since Thr-58 and Ser-62 have previously been 
shown to be involved in Myc turnover as discussed above, it was therefore of 
interest to determine if the phosphorylation of these sites were affected by IFN-γ 
treatment. For this purpose specific anti-phospho-T58/S62-Myc antiserum was 
used in western blot analysis. The results showed that the level of phosphorylated 
Myc declined after both IFN-γ alone and IFN-γ + TPA treatment in comparison 
with total Myc. We concluded from these results that IFN-γ stimulation led to 
dephosphorylation of Ser-62 irrespective of the Thr-58 status since v-Myc has 
mutated Thr-58. To examine whether Ser-62 was essential for IFN-γ induced 
degradation, the turnover of c-Myc-wt and T58A and S62A mutants in response to 
IFN-γ was studied in 2FTGH cells. Cycloheximide chase analysis showed that 
IFN-γ  increased the rate of degradation of wild type and T58A-c-Myc but not of 
the S62A-c-Myc mutant, suggesting a rate of Ser-62 in IFN-γ -induced  Myc   42
degradation. In conclusion, IFN-γ  treatment decreased Myc phosphorylation on 
Ser-62 and IFN-γ -induced Myc degradation was shown to be Ser-62 dependent 
and Thr-58 independent.  
Our data thus provide evidence that thus antiproliferative signaling leads to 
decreased Ser-62 phosphorylation of Myc which in turn increases Myc 
degradation. Certainly we can not exclude other sites which can be affected in 
response to IFN-γ treatment. 
 
CDK2 phosphorylates Myc at Ser-62 in vivo and in vitro 
 
Our results indicated that dephosphorylation of Ser-62 leads to destabilization of 
Myc, suggesting that phosphorylation of Ser-62 might stabilize Myc. The kinase 
that phosphorylates Ser-62 in vivo has not been clarified, but previous work has 
suggested that both MAPK and CDC2 can phosphorylate Myc at Ser-62 in vitro 
(Seth et al., 1992, Lutterbach and Hann, 1994). In an attempt to identify the in 
vivo Ser-62 kinase, we cotransfected U2OS cells with Flag-c-Myc together with 
CycE/CDK2 or with constitutively active Ras, which activates the MAPK 
pathway. In addition, cells were treated with the Cdk2 inhibitor roscovitine, 
(Meijer et al., 1997) or dominant negative Ras (Dn-Ras) which block this 
pathway. Western blot analysis showed that the phospho-Myc signal was reduced 
after roscovitine treatment. Whereas CycE/CDK2 increased phosphor-Myc 
compared to the total Myc level. However, neither activated nor dominant 
negative Ras seemed to affect Myc phosphorylation. This suggests that CDK2 
stimulates Myc phosphorylation in vivo.  
To confirm whether Myc is a CDK2 substrate, we performed an in vitro kinase 
assay using bacterially expressed wt Myc and mutants Myc GST-fusion proteins 
incubated in the presence of (γ -32P) ATP with purified CycE/A-CDK2 
complexes expressed in baculovirus. The results showed that wt Myc and Myc-
T58A but not Myc-S62A were phosphorylated efficiently by the CycE/CDK2 
complex, and to a lesser extent by CycA/CDK2. In conclusion, our in vitro and in 
vivo results suggested that CDK2 is a Ser-62 kinase. 
To investigate the effect of roscovitine on Myc turnover, v-Myc expressing U937 
cells were treated with roscovitine for two hours followed by cycloheximide 
chase. The results showed that roscovitine increased the rate of degradation of 
both c-and v-Myc (from 28, 120 to 20, 40 minutes respectively). We conclude that
 
dephosphorylated of Myc is through inhibition of CDK2 in vivo, by the CDK2 
inhibitor roscovitine, leads to increased c-and v-Myc turnover, thus mimicking the 
effect of IFN-γ. 
 
IFN-γ increases Myc degradation and dephosphorylation through CDK2 
inactivation via p21
Cip1 and p27
Kip1 upregulation 
 
The current dephosphorylation of Myc could either be the result of activation of a 
phosphatase or inactivation of a Ser-62 kinase in response to IFN-γ treatment.  
To investigate if CDK2 activity was affected by IFN- γ stimulation, v-Myc 
expressing U937 cells treated with IFN-γ, TPA, or both in combination, an in vitro 
cdk2 kinase activity assay was performed using histone H1 as a substrate and cdk2 
immunoprecipitated from the cells. In presence of [γ-32P]-ATP we readily   43 
detected the phosphorylation of histone H1. We observed that IFN-γ alone and 
IFN- γ+TPA led to strongly decreased phosphorylation of histone H1 suggesting 
that IFN-γ treatment inactivated CDK2 complexes. A slight reduction was 
observed also after TPA treatment 
Rb is an in vivo substrate for both CycD/CDK4 and CycE/CDK2. Immuno-
precipitation of Rb showed that IFN-γ treatment resulted in reduced Rb 
phosphorylation in both parental and v-Myc expressing cells. These results 
confirm that IFN-γ treatment inactivates CDK4 and/or CDK2 in U937 cells. 
We next investigate whether the IFN-γ-induced CDK2 inactivation correlated to 
upregulation of CKIs expression as has been suggested by previous report  (Harvat 
et al., 1997, Takami et al., 2002). Our results confirmed that IFN-γ and TPA 
costimulation induced the expression of p27
Kip1 and p21
Cip1 in v-Myc transformed 
U937 cells. However in contrast to p27
Kip1, p21
Cip1 expression was not increased 
by IFN-γ alone but required costimulation with TPA, further, increased interaction 
of CDK2 with p27
Kip1 was found by coimmunoprecipitation analysis in response to 
TPA, IFN- γ and IFN- γ+TPA stimulation in U937 cells, suggesting that p27
Kip1 is 
a main player in the IFN- γ inactivation of CDK2 complexes. However we can not 
fully exclude other possible mechanisms such as inactivation of CAK which is 
involved in activation of CDK. CDK2 inactivation can also occurs through other 
mechanisms such inactivation of an upstream kinase involved in activation of the 
kinase that phosphorylates Myc. 
We next studied the kinetics of CDK2 inactivation after in IFN-γ + TPA treatment 
in v-Myc transformed U937 cells, by in vitro CycE/CDK2 kinase assay as above. 
The result showed that CycE/CDK2 activity was down-regulated within 4 hours of 
IFN-γ + TPA treatment, thus correlating kinetically with upregulation of both 
p21
Cip1 and p27
 Kip1. 
The inactivation of CDK2 by IFN-γ  could further be connected kinetically to the 
reduced phosphorylation of Ser-62 as determined by western blot using phospho-
Myc antisera. The turnover rate of Myc was determined in v-Myc expressing 
U937 cells treated with IFN-γ + TPA for 4 and 8 hours and followed by a 
cycloheximide chase experiment and showed that Myc turnover increased already 
within 4 hrs of by IFN-γ + TPA treatment, thus confirming that Myc degradation 
correlated kinetically with Myc dephosphorylation, inactivation of CDK2 and 
upregulation of CKIs in response to IFN-γ 
To exclude that the effect of IFN-γ and roscovitine treatment on Myc-Ser62 
dephosphorylation and degradation was not due to  indirect effects on the cell 
cycle, we analyzed the cell cycle of distribution v-Myc- transformed U937 cells 
kinetically after IFN-γ+TPA, or roscovitine treatments. The result demonstrate that 
neither IFN-γ+TPA nor roscovitine treatment altered the cell cycle distribution at 
early time point, when the effects of Myc was observed, whereas  G1   
accumulation was indeed observed at 24 hours after treatment with IFN-γ + TPA, 
as previously reported (Oberg et al., 1991). In conclusion these events occurred 
prior to effects of IFN-γ on the cell cycle, excluding that Myc was affected 
indirectly through the cell cycle arrest. An alternative explanation for the observed 
Myc dephosphorylation in response to IFN-γ could be activation of a Ser-62 
phosphatase. Analysis of PP2A which was recently reported to dephosphorylate 
Ser-62 (Yeh et al., 2004) showed that its activity was not altered by IFN-  44
γ treatment, we can however not entirely exclude other phosphatases that might 
affects by IFN-γ stimulation. 
 
IFN-γ induced Myc degradation is p27
Kip1 dependent moreover p27 induced 
degradation is Ser-62 dependent and Skp2 independent manner 
 
These results suggested that p27
Kip1 might be a key player in mediating the anti-
Myc activity of IFN-γ. 
To further investigate the role of p27
Kip1 in Myc dephosphorylation and 
degradation. HeLa cells were cotransfected with wt-Myc or T58A and S62A 
mutants together with p27
Kip1. We observed that overexpression of p27
Kip1 reduced 
the mount of phospho-Myc relative to the total amount of Myc for both wt-Myc 
and the T58A mutant. Further p27
 Kip1 overexpression induced Myc degradation in 
both Myc-wt and Myc-T58A mutant but not in S62A mutant, suggesting that 
p27
Kip1 induced-Myc degradation is Ser-62 dependent. 
To determine whether IFN-γ-induced degradation of c-Myc is p27
Kip1-dependent, 
we used wild-type and p27-/- MEF cells. Western blot analysis showed IFN-γ 
increased Myc degradation in wt but not in p27-/- MEF cells, suggesting that 
p27
Kip1 is indeed required for IFN-γ-induced degradation of c-Myc. Taken together 
our data suggest that IFN-γ-induced Myc degradation is p27
Kip1 dependent 
emphasizing the role of p27
Kip1 in regulation of Myc degradation and inactivation. 
Paper II and (Kim et al., 2003) showed that the E3 ubiquitin ligase SKP2 interact 
with Myc and directs its ubiquitylation and degradation in Thr-58 independent 
manner (Kim et al., 2003, von der Lehr et al., 2003). It was of interest to 
determine whether Skp2-induced Myc degradation is Ser-62 dependent. 
Cotransfection of HeLa cells with wt-Myc or the S62A mutant together with Skp2 
and Cul1, showed that Skp2/Cul1 induced degradation of the S62A mutant as 
efficient as wt-Myc, suggests that Skp2-induced degradation is independent of 
Ser-62. Addressed the role of Skp2 in p27-induced-Myc degradation, 
cycloheximide chase experiments showed that c-Myc was stabilized in Skp2∆F 
cotransfected cells as shown in paper II. However, p27
Kip1 cotransfection increased 
Myc degradation irrespective of the presence of Skp2∆F suggesting that Skp2 
does not participate in p27
Kip1-induced Myc degradation. Interestingly this 
suggests that a distinct E3-ligase might be involved in IFN-γ and p27
Kip1-induced 
Myc degradation. The identification of this E3 ligase requires further 
investigation. 
In conclusion our results suggest that IFN-γ induced signals inhibit Myc function 
through dephosphorylation of Myc at Ser-62 resulting in increased c-and v-Myc 
degradation via the ubiquitin/proteasome pathway. This dephosphorylation and 
destabilization occur through inactivation of CDK2 via upregulation of p27
Kip1. 
This evidence proves that p27
Kip1 is both required and sufficient for Myc 
degradation and Ser-62 dephosphorylation.  
   45 
Discussion paper III and IV 
 
Interferon-gamma has long been known as antiproliferative cytokine. However the 
mechanism of its antiproliferative action is not fully understood. Previously has 
shown that IFN-γ with TPA costimulation restores
 terminal differentiation and G1 
cell-cycle arrest despite continuous
 expression of v-Myc. These findings suggested 
that IFN-γ +TPA combination can interfere with the growth and blocking Myc 
activity. In paper III we initiated our work with investigating the mechanisms 
behind IFN-γ effect.  We envisioned that these signals could counteract Myc by at 
least
 three different mechanisms. First, by increased expression or
 activity of Myc-
antagonist members of the mad-family. Second, by acting on Myc
 directly through 
inhibition of its activity or through affecting
  its steady state level by a 
posttranslational mechanism. Third,
 by acting downstream of Myc; for instance, 
through independent
 regulation of Myc target
 genes. 
We found that induced expression of Mad1 occurred only transiently in v-Myc
 
expressing cells (Figs 2, 4, and 6 . In paper III). This indicates a direct or
 indirect 
role of Myc in the regulation of the mad1. Since, costimulation
 with IFN- niether 
increased the expression of other mad genes or mnt mRNA (data not shown), 
these results argue against
 our first hypothesis. 
In contrast, IFN-γ costimulation with TPA reduced the both DNA binding activity 
of both v- and c-Myc and their hetrodimerization with Max. This suggest that 
IFN-γ+TPA inhibit Myc activity at least, in part by direct interference with the 
disassociation of Myc:Max complexes and decreased DNA binding rather than 
competition with Mad. Indeed Myc activity is dependent on dimerization with its 
obligate partner, Max. These findings likely explain the inhibition of Myc-induced 
transcription from its target promoters, since Myc needs to interact with Max and 
bind DNA in order to activate transcription. In addition to these observations we 
found that IFN-γ alone or in combination with TPA dephosphorylated Myc in one 
or several phosphorylations sites.  In fact, Max is constitutively phosphorylated in 
vivo at protein kinase CKII sites, including Ser2 and Ser11. This phosphorylation 
has been shown to affect the DNA-binding properties of Max homodimers. 
(Berberich and Cole, 1992, Bousset et al., 1993, Bousset et al., 1994). Myc also 
has CK II phosphorylation sites in similar positions, but it is unclear if they affect 
DNA binding. The central acidic region of Myc also contains several sites of 
phosphorylation which can be phosphorylated by CKII (Luscher et al., 1989).  
Several recent studies has shown that Myc phosphorylation can be involved in 
stabilization of the protein (see paper I) (Noguchi et al., 1999, Bahram et al., 2000, 
Gregory and Hann, 2000, Sears et al., 2000, Noguchi et al., 2001) or its ability to 
promote transformation (Bousset et al., 1993, Lutterbach and Hann, 1994). In 
addition phosphorylation of Myc at unidentified sites has shown to inhibit Myc 
DNA binding during mitosis, (Luscher and Eisenman, 1992). Interestingly, 
recently work from (Huang et al., 2004) has demonstrated that phosphorylation of 
Myc at Thr-358, Ser-373 and Thr-400 by Pak2 in response to stress related 
signals, reduces Myc DNA binding and phosphorylation of Ser-373 and Thr-400 
blocks Myc: Max dimerization. These observation suggest that different signals 
involved in phosphorylation or dephosphorylation of Myc can affect its DNA 
binding and dimerization. It would be interesting to investigate whether IFN-γ can 
affect phosphorylation at the C-terminus sites regulated by stress signals.     46
Moreover Myc has been shown to have multiple phosphorylation sites in the N-
terminal region, where Thr-58, Ser-62 and Ser71 may be most functionally 
significant. (As discussed in paper I and II). In an attempt to further elucidate the 
mechanism(s) of IFN-γ induced Myc inactivation, we addressed whether IFN-γ 
might be involved in Myc degradation. Our present results show that stimulation 
with IFN- γ alone or together with TPA increased degradation not only of c-Myc 
but also of v-Myc, which carries a stabilizing mutation at Thr-58 (see paper I). We 
have also demonstrated that IFN-γ induced degradation was not cell line specific 
since we have also observed IFN-γ induced degradation in Colo320 colocarcinoma 
and in human fibrosarcoma cells. Further, we found that IFN-γ-stimulated 
turnover of Myc was compromised in STAT1 or JAK deficient cells’, suggesting 
that it is STAT1/JAK1 dependent. It is however, still not unclear how the IFN-γ-
induced activation of STAT1 leads to inactivation of Myc.  
To our knowledge this is the first report demonstrating that Myc turnover can be 
regulated by antiproliferative signaling. Since we have shown in paper III that 
Myc was dephosphorylated after IFN-γ treatment, these observations raised the 
question whether there might by a connection between dephosphorylation and 
increased degradation by IFN-γ. Two candidates for Myc phosphorylation sites 
affected by IFN-γ were Thr-58 and Ser-62, which both has been implicated in Myc 
turnover (see paper I). Investigating the status of these phosphorylation sites we 
found that IFN-γ stimulation led to dephosphorylation of Ser-62 irrespective of the 
Thr-58 status, which in turn increases Myc ubiquitylation and degradation in Ser-
62 dependent and Thr-58 independent manner. Surprisingly, mutation of S62 to 
alanine stabilized Myc in untreated cells. The reason for that is unclear, but may 
be due to decreased Thr-58 phosphorylation as a result of the prevention of Ser-62 
phosphorylation as previously suggested (Bousset et al., 1993 44, Lutterbach and 
Hann, 1994 47, Pulverer et al., 1994 46). Although regulation of Ser-62 seems to 
play a crucial role, we can not exclude that also other sites might be affected in 
response to IFN-γ treatment.   
Our results further suggest that CDK2 is a major in vivo and in vitro Ser-62 kinase 
(Fig 3 paper-IV). Previous reports have suggested that Ras activation can lead to 
Ser-62 phosphorylation through MAPK which can phosphorylate Myc at Ser-62 in 
vitro (Seth et al., 1992, Lutterbach and Hann, 1994). However, neither 
constitutively active nor dominant negative Ras affected Ser-62 phosphorylation 
in our cell systems arguing against MAPK as a major in vivo Ser-62 kinase. This 
conclusion is supported by (Lutterbach and Hann, 1999). However, we still can 
not exclude that MAPK could phosphorylate Ser-62 in other cells or under other 
conditions.   
Several signal-mediated pathways have previously been connected to regulation of 
Myc stability. Among these is the Ras/MAPK pathway, which has been suggested 
to increase Myc stability through phosphorylation of Ser-62, (Sears et al., 1999). 
In addition, the activation of MEKK1/JNK by UV or the necrosis factor-alfa 
(TNF-α), and has been suggested to stabilized Myc (Park et al., 1998, Yujiri et al., 
1998, Alarcon-Vargas et al., 2002, Alarcon-Vargas and Ronai, 2004). The action 
in this case seems to involve in activation of PI-3K/AKT resulting in inactivation 
of GSK-3, which in turn leading in preventing of Thr-58 phosphorylation resulting 
in Myc stabilization, (Sears et al., 2000, Venter et al., 2001)   47 
Dephosphorylation of Myc could either be the result of activation of a Ser-62 
phosphatase or inactivation of the Ser-62 kinase. The PP2A Ser/Thr phosphatase 
was recently shown to dephosphorylate Myc at Ser-62 in Thr-58 phosphorylation 
and Pin1 dependent manner (Yeh et al., 2004). However, we could demonstrate 
that the activity of PP2A was not altered by IFN-γ treatment. Although we can not 
entirely exclude the involvement of other Ser/Thr phosphatases, we speculated 
that IFN-γ stimulation might inhibit CDK2 activity, for instance by upregulation 
of CDK inhibitors. It has been reported previously that IFN-γ induces p27
Kip1 and 
p21
Cip1 in certain cells (Harvat et al., 1997, Takami et al., 2002). Here we 
confirmed that IFN-γ and TPA costimulation induces the expression of p27
Kip1 and 
p21
Cip1 in v-Myc transformed U937 cells. However in contrast to p27
Kip1, p21
Cip1 
expression was not increased by IFN-γ alone but required costimulation with TPA 
in U937 cells. Our findings suggest that p27
Kip1 is a main player in the IFN- γ 
inactivation of CDK2 complexes. However, we can not fully exclude other 
possible mechanisms such as inactivation of CAK which is an upstream kinase 
involved in activation of CDK, or alternatively inactivation of the phosphatases 
that are involved in activation of CDKs such as cdc25 family proteins. 
Interestingly, we found that CDK2 inactivation occurs early after IFN-γ+TPA 
treatment in parallel with the increased expression of p27
Kip1 and p21
Cip1. This 
correlated kinetically with the dephosphorylation of Myc at Ser-62 and the 
increased c- and v-Myc degradation after IFN-γ treatment. These events occurred 
prior to effects of IFN-γ on the cell cycle, excluding that Myc was affected 
indirectly through cell cycle arrest. The role of p27
Kip1 was further emphasized by 
the observation that overexpression of p27
Kip1 decreased Myc phosphorylation at 
Ser-62 and induced Myc degradation in Ser-62 dependent manner. Furthermore, 
utilizing p27-/- MEF cells we could show that IFN-γ-induced Myc degradation is 
p27
Kip1 dependent. Taken together our data strongly suggest an important role of 
p27
Kip1 in regulation of Myc degradation and inactivation.  
We and others recently showed that the E3 ubiquitin ligase Skp2 interact with 
Myc and directs its ubiquitylation and degradation in Thr-58 independent manner 
(Kim et al., 2003, von der Lehr et al., 2003). Interestingly we found that IFN-γ and 
p27
Kip1-induced Myc degradation and inactivation were independent on Skp2. In 
contrast to IFN-γ, Skp2 cooperates with Myc to induce G1/S-phase transition and 
to activate target genes Myc transactivation, suggesting that Myc transactivation 
could be positively or negatively regulated through ubiquitylation by different E3-
ligases. This suggests that a distinct E3-ligase might be involved in IFN-γ and 
p27
Kip1-induced Myc degradation. The identification of this E3 ligase requires 
further investigation. We also hypothesizes that Ser-62 phosphorylation might be 
involved in reducing of E3-ligase binding to Myc resulting in stabilization of Myc. 
Another option is that Thr-58 and Myc Ser-62 phosphorylations both are involved 
in intracellular localization of Myc such as nuclear import and export. 
In conclusion our results suggest that IFN-γ+TPA stimulation restores 
differentiation and cell cycle arrest of v-Myc expressing U937 through 
posttranslational modification of c-and v-Myc by dephosphorylation at Ser-62 
resulting in increased v-and c-Myc degradation via the ubiquitin/proteasome 
pathway. This may not exclude that some of the effects of IFN-γ on Myc observed 
in paper III may be generated via distinct IFN-γ-induced signals. This 
dephosphorylation and destabilization occur through inactivation of CDK2 via activation of p27
Kip1. Our results suggest that p27
Kip1 is both required and 
sufficient for Myc degradation and Ser-62 dephosphorylation. Various reports 
have shown that Myc regulates p27
Kip1 activation and degradation in response to 
proliferative signals. Here we show p27
Kip1 in turn is able to regulate the activity 
and stability of Myc in response to anti-proliferative signals. Such negative 
regulation of c-Myc generally and Myc with mutated Thr-58 by cytokine signals 
might be a biologically relevant level of control with potential therapeutic 
relevance for tumors with deregulated Myc-expression.  
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Φιγυρε 6: Ηψποτηετιχαλ µοδελ οφ ΙΦΝ−γαµµα−ινδυχεδ ινηιβιτιον οφ χ−Μψχ πηοσπ
ηορψλατιον τηρουγη Χδκ2/π27Κιπ1 ρεσυλτσ ιν χ−Μψχ υβιθυιτιν/προτεασοµαλ δεγ
ραδατιον    
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CONCLUSIONS 
 
1 The Myc oncoprotein is degraded via the ubiquitin-proteasome pathway. 
 
2 Thr-58 mutation results in inefficient ubiquitylation and decreased proteasome-
mediated turnover.  
 
3 The SCF
Skp2 E3 ubiquitin ligase interacts with c-Myc and participates in Myc 
ubiquitylation and degradation in a Thr-58 independent manner. 
 
4  SCF
Skp2  is coactivator for Myc induced transcription. 
 
5 IFN-γ costimulation with TPA inhibits Myc-induced transcription and DNA 
binding through Myc:Max destabilization, correlating with posttranslational 
modification of Myc by dephosphorylation. 
 
6 IFN-γ decrease Ser-62 phosphorylation and increases Myc ubiquitin-
proteasome-mediated degradation in Ser-62 dependent manner. 
 
7 CDK2 is an in vivo and in vitro Ser-62 kinase. 
 
8 IFN-γ increases Myc Ser-62 dephosphorylation and degradation through 
inactivation of CDK2 via p27
Kip1. 
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